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Abstract
Gene Modification with Triplex-Forming Oligonucleotides 
Jennifer M. Kalish 
2006
Triplex-forming oligonucleotides (TFOs) bind DNA in a sequence-specific 
manner and mediate targeted genome modification. Triplexes bind parallel to the purine 
strand of the duplex in the pyrimidine m otif and anti-parallel in the purine motif. TFOs 
in both motifs have been shown to direct psoralen adduct formation in cells, leading to 
mutagenesis or recombination. Only purine motif TFOs have been shown to mediate 
genome modification without using a DNA-adduct. In this work, we report the ability of 
a series o f chemically modified pyrimidine m otif TFOs to induce repair and 
recombination in the absence of any DNA-reactive conjugate. We find that a number of 
modified TFOs show increased formation of non-covalent triplexes under physiological 
conditions. However, only the N3'->P5' phosphoramidate and 5-(l-propynyl)-2'- 
deoxyuridine-modified TFOs mediate induced recombination in cells and stimulate repair 
in cell-free extracts. Additionally, we establish the ability o f TFOs to induce gene 
correction at a single-copy chromosomal locus in mammalian cells at frequencies up to 
0.1%. We demonstrate sequence, target site, and dose-dependent effects. Finally, we 
develop an assay to detect incisions made in repair o f a triplex. This work expands the 
number o f targets available for triplex-mediated gene targeting, shows effective targeting 
at a chromosomal locus, and takes first steps towards understanding the mechanism of 
triplex-induced gene correction.
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Chemical Structures
° _Y o ^ aBe
ijjH 
o-y~o -
° ~ 1̂ ° ^ a s e
(iH 
0= f-0  -
a m i d a t e  9
9 y-+NH 
0 = f-N H -----'  , Vs—
n ^ T e )
9 / — +NH 
0 « |- N H ---- '  Nv'~
DEED 9
°fer^pr





o = f - o  - 0 |
0
0= f - 0 -
5m eC  ^
I  >*c h 3
0= P -0  -
° ^ c y
9
0 = P - 0 -
p d U  9
0 "O 
0 = ?“0 -r\^ r
9 ^ 0  
0 = 5>-0 - 
9
LNA *
0  O M e  
0 = f ~ 0 -
° 1 ^ o ^ a s e
o O M e  
0 = f - 0 -
2 1-O -M e  9
W
9 o
0 = f - 0 -
0~ v ° - ^ a s e
y - / ^ NH2
0 » f > - 0  -
2 ' - AE  9
b a s e
^ — N
X 1
- 'N 'p - o  b a s e
^ N - f = 0  
m o r p h  ^
Structures of the chemical modifications. N3'->P5' phosphoramidate (amidate); N, N- 
diethylethylenediamine (DEED); N, N-dimethylaminopropylphosphoramidate (DMAP); 
5-methyl-2'-deoxycytidine (5meC); 5-(l-propynyl)-2'-deoxyuridine (pdU); 2'-0, 4'-C- 
methylene bridged or locked nucleic acid (LNA); 2'-0-methyl-ribose (2'-0-Me); 2'-0-(2- 
aminoethyl)-ribose (2’-AE); morpholino (morph).
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Appendix 2
I
Nucleotide excision repair pathway. The parallel pathways of global genome repair 
(GGR) and transcription-coupled repair (TC-NER) recognize helically distorting lesions 
in DNA and polymerase blocking lesions in transcribed regions of DNA, respectively. In 
GGR, XPC-hHR23B recognizes helical distortions and in TC-NER lesions are 
recognized by blockage of RNA polymerase II. In GGR, TFIIH and possibly XPG are 
attracted to XPC-hHR23B bound to the lesion. TFIIH creates an open complex via XPB 
and XPD, leading to the recruitment of XPA and RPA, and to the common incision 
pathway. In TC-NER, CSA, CSB, TFIIH, XPG, and possibly other factors, replace RNA 
polymerase II, leading to the recruitment o f XPA and RPA, and to the common incision 
pathway. The incision pathway consists o f XPG making the 3' incision and ERCC1-XPF 
making the 5' incision. After the dual incision is completed, gap-filling DNA synthesis 
occurs followed by ligation. This is an adaptation o f a figure from de Laat, W.L., et al., 
(1999). Genes and Development 13: p. 768-785.
xii
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Triple helix (triplex) formation was first described in 1957 by Felsenfeld and 
colleagues, who while studying polypurine/polypyrimidine duplex interactions, noted the 
binding of a second polypyrimidine strand to the duplex [1], Triplex-forming 
oligonucleotide (TFO) binding occurs under physiologic conditions and in a sequence 
specific manner [2-5]. The target specific binding of TFOs has been used to deliver DNA 
interacting molecules to a specific genetic location. While binding to the double helix, 
TFOs alter the helix and induce cellular repair mechanisms. These repair mechanisms 
lead to TFO alteration of gene metabolism via transcription repression, inhibition of 
DNA replication, and induction of site-specific mutagenesis and recombination [6-11]. 
Thereby, TFOs have the potential to introduce permanent changes in genomic DNA in a 
variety of contexts.
Triplex Chemistry and Binding Code
TFOs bind DNA in the major groove of DNA in a sequence-specific manner to 
homopurine sequences in two distinct motifs [2-4, 12]. Triplex formation is favored at 
polypurine/polypyrimidine regions o f DNA and can occur with the third strand oriented 
either parallel or anti-parallel to the purine strand of the duplex. TFOs bind to duplex 
DNA using an alternative set of hydrogen bonds called Hoogsteen bonds [1], Purine 
motif TFOs bind anti-parallel to the duplex via reverse-Hoogsteen hydrogen bonds and 
pyrimidine motif TFOs bind parallel via Hoogsteen bonds [2-4, 12]. In the anti-parallel,
1.2
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purine motif, the triplets are G.G:C and A.A:T; whereas in the parallel, pyrimidine motif, 
the canonical triplets are C+.G:C and T.A:T (Fig. 1). In the pyrimidine motif, protonation 
of the cytidine is required for triplex formation [3, 13, 14].
Chemical Modifications
To enhance the biological activity of TFOs there has been a focus on chemical 
modifications (Appendix 1). Under physiologic conditions, potassium levels are high, 
magnesium levels are low, and pH is neutral. High potassium promotes G-quartet 
formation, which inhibits the activity of G-rich purine motif TFOs [15-17], Magnesium 
supports third-strand binding by charge neutralization. Neutral pH disfavors cytosine 
protonation, which is needed for triplex formation in the pyrimidine motif, unless the 
cytidines are modified [3, 13, 14]. As a result, a variety o f chemical modifications have 
been explored to offset the effects of these factors on TFO binding and thereby increase 
binding affinity and enhance potential biological activity o f the TFOs. These 
modifications include sugar, backbone, and base modifications.
Purine M otif Modifications
Chemical modifications such as N, N-diethylethylenediamine (DEED) have been 
used to enhance binding and thereby the biological activity of TFOs in the purine motif 
[18-22], The G-rich nature of purine motif TFOs allows them to form G-quartets under 
physiological conditions which include high levels of potassium [15-17],
1.3
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7-deazaxanthine and 6-thioguanine substitutions have been used to offset the diminished 
TFO binding in the presence of high levels of potassium (due to the formation of G- 
quartets), and such molecules have shown increased effectiveness in cells [23-25].
Pyrimidine M otif Modifications
For triplex formation in the pyrimidine motif, an acidic pH is needed for N3 
protonation of cytidines (C) [14]. Therefore, TFOs with several adjacent C’s require a 
lower pH for binding to duplex DNA than TFOs with dispersed C’s [14, 26]. TFOs with 
5-methyl-2'-deoxycytidine (5meC) [27-29] and 5-(l-propynyl)-2’-deoxyuridine (pdU)
[29] substitutions were shown to alleviate the need for an acidic pH and to improve the 
effectiveness of mutagenesis targeted by TFO-conjugated delivery of 4'-hydroxymethyl- 
4, 5', 8-trimethylpsoralen (psoralen) to specific sites. Other demonstrated base 
substitutions for cytidine include: pyrrolidino pseudoisocytidine [30], 8-oxoadenine [31, 
32], N7-2'-deoxyguanosine [33], 7,8-dihydro-8-oxoadenine [34], 8-oxo-2'- 
deoxyadenosine [35, 36], 2-aminopyridine [37], and 8-aminoguanine [38]. TFOs 
containing these modified bases have enhanced binding affinity at neutral pH compared 
to unmodified TFOs [30-38].
Sugar substitutions such as 2'-0-aminoethyl (2'-AE) [39, 40] and 2'-0-methoxy 
(2'-OMe) [41, 42] enhance TFO stability and affinity for binding duplex DNA. Work by 
Michael Seidman’s group showed that 2'-0-aminoethyl and 2'-0-methoxy substitutions 
on psoralen-conjugated TFOs in the pyrimidine m otif enhance gene knock-out in 
mammalian cells [40], More recent work from this group demonstrated that only a
1.4
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
J. M. Kalish
minimal number of 2'-0-aminoethyl substitutions clustered together was sufficient for 
enhanced gene knock-out activity [43, 44],
Backbone modifications have also been extensively used to augment TFO binding 
affinity and intracellular activity through reduction o f charge interactions [45], 
Replacement of the bridging N3 oxygen with a nitrogen improved TFO binding in vitro 
[46] and when conjugated to psoralen these TFOs were used to target integrated J I1V-1 
pro virus within cell nuclei [47]. The TFO binding and psoralen delivery to chronically 
infected cells containing the HIV-1 pro virus was demonstrated using a restriction 
protection assay, where DNA digestion was prevented when the psoralen adduct was 
present at the correct target site[47]. Replacement o f a non-bridging oxygen with amino 
groups such as N, N-diethylethylenediamine (DEED), or N, N-dimethylamino- 
propylphosphoramidate (DMAP) as chemical modifications on the third strand have been 
used to enhance triplex formation under physiologic conditions [48]. Morpholino- 
modified TFOs have both a sugar and a backbone modification and can also form stable 
triplexes [49].
Peptide Nucleic Acids
The peptide nucleic acid (PNA) resembles DNA, with purine and pyrimidine 
bases being attached to a polyamide backbone. PNAs can be used to mediate gene 
modification and bind to DNA in several different ways (Fig. 2). PNAs can bind through 
strand invasion to one or both of the strands o f the duplex [50, 51]. This binding is via 
Watson-Crick base pairing between the PNA and the DNA duplex and disrupts the DNA
1.5
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duplex binding to itself [52], PNAs can also form triplexes with a strand invading PNA 
conjugated to a flexible linker molecule with an additional sequence that can form 
Hoogsteen bonds with the PNA-DNA duplex [52], This PNA clamp binds to a single 
strand o f duplex DNA via both Watson-Crick base pairing and Hoogsteen base pairing 
[52]. PNAs have a greater binding affinity as third strands than unmodified TFOs of the 
same sequence [53], Mixed sequence (purine and pyrimidine) PNAs have been 
developed, which are an advantage over TFOs that only bind to AG-rich or TC-rich 
stretches o f DNA [54], The PNA clamp was demonstrated to induce XPA-dependent 
DNA repair and recombination [52], In order to expand the number of target sequences 
for PNA binding, tail-clamp PNAs which have an additional mixed (purine and 
pyrimidine) sequence as part of the strand invasion sequence have been developed and 
were shown to inhibit transcription [55, 56].
TFO-Targeted Gene Modification
TFOs as a tool fo r  delivery o f  DNA reactive agents
TFOs have been used to deliver DNA reactive molecules to specific locations on 
the DNA (Fig. 3A). In this regard, TFOs represent a means o f effective gene 
modification. The DNA-reactive agents include psoralen [57, 58], camptothecin (CPT) 
[59, 60], padlock TFOs [61-63], [5-(125)I]dCMP [64, 65], and acridine [66, 67], Based 
on the potential for molecular recognition of unique genomic sites, Havre et al. used a 
TFO to deliver psoralen in a sequence-specific manner [57, 58]. TFO delivery of
1.6
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psoralen followed by photo-activation of the psoralen, induced site-specific mutagenesis 
in viral DNA within mammalian cells [57, 58], Activation of gene expression has been 
demonstrated by pso-TFOs in a manner dependent on photo-crosslinking [68].
Topoisomerase I is a DNA-relaxation enzyme that is an important therapeutic 
target for CPTs in cancer chemotherapy. Camptothecins as agents alone do not bind to 
specific DNA regions, leading to drug side effects induced by the non-specific binding. 
CPT conjugation to a DNA targeting agent such as a TFO shows promise of increasing 
the specificity of drug delivery. Binding o f these CPT-TFO conjugates to duplex DNA 
has been demonstrated in vitro and their cellular activity has been demonstrated [59, 60].
Padlock TFOs are TFOs with extra sequences (complementary to each other) on 
either side o f the polypurine/polypyrimidine TFO binding sequence, the ends of which 
are ligated together with T4 ligase after TFO binding [62], This end-ligation forms a 
loop around the plasmid DNA containing the TFO binding site (TBS) [62] and has been 
used to conjugate targeting peptides to plasmids [61] and to inhibit transcription 
elongation [63], TFOs are also used to deliver [5-(125)I]dCMP which, after decay 
accumulation, causes double strand breaks in the targeted DNA [64, 65],
Binding Affinity Correlates with Intracellular Activity
Wang et al. showed that psoralen-conjugated TFOs transfected into monkey COS- 
7 cells can induce base pair-specific mutations within the supF  reporter gene in a simian 
virus 40 (SY40) genome in cells, at a frequency in the range of l%-2% [11], The key
1.7
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finding in this seminal work was that the binding affinity o f the TFO to its target site, as 
measured in vitro, was highly correlated with its intracellular activity. TFOs with Kd's 
(equilibrium dissociation constants) in the range o f lx l0 ‘9 M were active; those with Kd’s 
of lxlO"6 M were not. A more specific threshold has been determined for induced DNA 
recombination and repair, where a binding affinity greater than 1 x 1 0 ‘7 M  is necessary for 
induced recombination in cells and induced repair in cell-free extracts [18]. Binding 
affinity in vitro is influenced by Mg2+ and K+ concentrations and pH while in vivo 
chromatin structure and transcriptional activity are also important factors. Transcription 
through the target region substantially enhances TFO chromosomal targeting, suggesting 
that gene modification with TFOs may be more effective at chromosomal loci that are 
highly expressed [69],
The binding affinity of a TFO in the anti-parallel, purine motif is not only 
influenced by the number of mismatches at the binding site but is also influenced by TFO 
length. TFOs of length 30, 20, and 10 designed to bind to all or a portion of a 30 base 
pair polypurine site have K fs of 2x1 O'8 M, 3x1 O'7 M and SxlO’3 M, respectively [70], 
Correspondingly, the amount of induced repair in HeLa cell-free extracts decreased with 
TFO length (the 30-mer in the purine motif demonstrated the greatest induced repair, 
while the 20-mer and then the 10-mer showed lesser effects) [70], The pattern of 
mutations produced by TFO-targeted psoralen adducts on an episomal target in COS-7 
monkey cells is also influenced by the length of the TFO [71]. Additionally, excision of 
TFO-damaged DNA is inhibited by a linked 30-mer TFO (whereby the triplex extension
1 . 8
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exceeds the nucleotide excision repair (NER) canonical excision patch) but not by a 1 ti­
mer TFO [71].
TFO-Inhibition o f Transcription
Transcription has been inhibited by TFOs binding to a variety of promoters and 
other targets in and near genes of interest. TFOs were shown to reduce c-myc expression 
[6, 72, 73] and to inhibit Tat-dependent in vitro transcription [74], Inhibition of 
transcription is dependent on the accessibility o f the TFO binding site (TBS) when the 
DNA is bound in the nucleosome [21] and TFOs have been shown to access binding sites 
within the chromatin structure [47], TFOs covalently bound to duplex DNA and PNAs 
through strand invasion inhibit replication of plasmid DNA in vivo [75]. Chemically 
modified TFOs were also used to inhibit transcription. 2'-0-methyl-modified TFOs 
binding to DNA block recognition of duplex DNA by a eukaryotic transcription factor 
[76] and LNA-modifled TFOs inhibit transcription in vitro [77], Phosphoramidate 
modified-TFOs have been shown to inhibit transcription of several HIV genes [78-80], 
Dual conjugation to phenylacetate mustard enhanced inhibition o f Her2 gene expression 
[81]. Psoralen-conjugated TFOs were used to inhibit a gene involved in cutaneous 
imflammation [82], the human rhodopsin gene [83], and Ets2 transcription in prostate 
cancer cells [84], These successful inhibitions suggest that TFOs may be useful as agents 
to treat skin diseases, ocular defects, and prostate cancer.
PNAs have been shown to arrest transcription elongation by invading double­
stranded DNA and forming a stable (PNA)2/DNA complex [85]. Conjugation o f a PNA
1.9
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
J. M. Kalish
to a peptide containing eight lysines increased the inhibition of transcription [86] and 
lactose-modified PNAs had increased cellular update and inhibition of transcription [87], 
PNA triplexes presented a stable barrier to DNA polymerase extension [88]. Tail-clamp 
PNAs have been shown to bind duplex DNA and inhibit transcription [55]. PNAs have 
also been used to deliver peptides to act as transcription activators [89].
TFO-Directed Mutagenesis
Knock-out of chromosomal genes mediated by psoralen-TFOs has been 
demonstrated. In one study, the supF  reporter gene integrated into the chromosome of 
mouse fibroblasts was used as a target [90], Again, only high-affinity TFOs were active, 
achieving targeted mutagenesis frequencies o f 0.1%. In the supF  experiments, essentially 
unmodified G-rich oligonucleotides (except for 3'-end-capping) designed to bind in the 
anti-parallel motif were used. A set of experiments to target the hprt gene in hamster 
CHO cells, in contrast, used a series of T-rich psoralen TFOs (because the A-rich target 
favored the parallel motif) [42]. In these experiments, the unmodified TFOs were 
ineffective. A second conjugation of the TFO to an intercalator, either acridine or 
pyrene, was needed to provide additional binding affinity [42], Such doubly modified 
TFOs yielded hprt mutagenesis at frequencies in the range of 10'3. More recent studies 
have demonstrated that pyrimidine TFOs substituted with 2'-aminoethyl sugar residues 
are highly active in targeting psoralen adducts and thereby mutations to the hprt gene, 
with frequencies in the range of 0.14% [43]. Psoralen conjugated PNAs were effective in
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inducing mutagenesis as well [91]. TFO-induced mutagenesis was also seen secondary 
to double strand breaks with [5-(125)I]dCMP labeled TFOs [64, 65],
However, the mutagenesis induced in the supF and hprt chromosomal targets, 
while site-specific in the sense that all the mutations clustered around the third-strand 
binding site, was somewhat variable. Hence, these experiments suggested that psoralen- 
coupled TFOs may be useful for gene-specific knock-out but not necessarily for 
predictable base pair-specific mutagenesis. As a research tool, however, psoralen TFOs 
have served as useful reagents to prove the ability o f oligonucleotides to bind as third 
strands to chromosomal sites in living cells. The importance of these results is to 
establish the concept that DNA binding molecules can be used to direct site-specific 
genome modification and to show that the cell and nuclear membranes and the packaging 
of the DNA into chromatin are not insurmountable barriers to gene targeting with 
antigene oligonucleotides.
TFO-Directed Mutagenesis without Psoralen Conjugation
In the course of the work with psoralen TFOs, Wang et al. observed that 
unconjugated TFOs were also capable o f inducing mutations in the target gene, at least 
when the binding affinity was sufficiently high (Fig. 3A) [70], TFOs can induce 
mutations in a sequence-specific manner in somatic cells in adult mice [10]. Transgenic 
mice carrying multiple copies of lambda vector DNA in their genome were injected 
intraperitoneally with a G-rich TFO specific to the target site (Fig. 4) [10]. TFO-induced 
mutagenesis was detected in a wide variety of tissues including skin, liver, kidney, and
1.11
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
J. M. Kalish
lung [10]. Again, the mutations were generally within the TFO target site. PNAs have 
also been used to target the chromosomal supF  reporter gene, in mouse cells, yielding 
frequencies of mutagenesis of 0.1% (10-fold above background) [92], PNA-induced 
mutagenesis was target specific with the majority o f mutations falling within the PNA 
binding site.
TFO-Induced Recombination
Based on the concept that third-strand binding, with or without psoralen coupling, 
can trigger DNA repair, Faruqi et al. hypothesized that such binding might also be 
recombinogenic due to the production of repair-dependent DNA strand breaks [8, 9]. To 
test this, two distinct recombination assays were used, intramolecular and intermolecular 
(Fig. 3B). Using an SV40 vector containing two mutant copies of the supF gene (Fig.
5A), they found that both psoralen conjugated purine motif TFOs [8] and TFOs without 
psoralen can stimulate intramolecular recombination [9]. This induced recombination in 
the case of the TFO without psoralen was found to be dependent on the presence of 
functional XPA protein [9],
These results were extended to a chromosomal target, in which two mutant 
thymidine kinase (TK) genes were integrated as direct repeats into a single chromosomal 
site in mouse fibroblasts (Fig. 5B) [93]. High-affmity TFOs targeting a region in 
between the two TK genes yielded recombination at a frequency of approximately 10"4, 
about 100-fold above background. When the TFOs were micro-injected into the nuclei of 
the cells (-2000 copies/cell), the yield o f recombinants increased to l%-2%, 10,000-fold
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over background [94], Analysis of the recombinant clones revealed all the recombination 
events involved gene conversion rather than crossover recombination [93],
Repair Pathways and TFO Effects
The TFO mutagenesis effect was shown to be a consequence of the stimulation of 
DNA repair by the formation of a triple helix, which can be recognized by the nucleotide 
excision repair (NER) complex as a "lesion" (Appendix 2). TFO-induced mutagenesis 
was not detected in cells deficient in XPA (a key NER recognition protein) but was 
restored in cells that were complemented with XPA cDNA[70]. Similarly, triplex- 
induced mutagenesis was not detected in Cockayne’s syndrome (CS) group B cells (cells 
deficient in transcription-coupled repair) but was detected in the cDNA corrected cell line 
[70], Thus, both the overall NER pathway and the transcription-coupled repair pathway 
play a role in triplex-induced mutagenesis. Gene activation by TFOs was unchanged in 
XPA, XPD and XPG deficient cell lines, thus gene activation is dependent on other repair 
pathways as well [68].
Intermolecular recombination between plasmid targets and short DNA fragments 
can be detected in human cell-free extracts, in a process that is dependent on XPA and 
Rad51 [95]. TFO-induced recombination in an episomal target in cells is also dependent 
on the NER pathway [9]. The repair and replication complex, replication protein A 
(RPA) recognizes triplex structures but also forms nonspecific DNA aggregates at higher 
concentrations [96]. In the presence of RPA, XPA binds to the triplex structure and
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decreases the non-specific binding of RPA [96]. Therefore, the synergy of RPA and 
XPA confers specificity and stringency for triplex lesion binding, and likely represents a 
key recognition step in the repair of triplex structures.
Donor Effects
The observation of the ability of third-strand binding to provoke DNA repair and 
stimulate recombination led to the development of a strategy to mediate targeted gene 
conversion using a TFO linked to a short DNA fragment homologous to the target site 
(except for the base pair to be corrected) (Fig. 3B) [97]. In this bi-functional molecule, 
the TFO domain mediates site-specific binding to target the donor molecule to the desired 
gene [97], This binding also triggers repair to sensitize the target site to recombination 
[97]. The tethered homologous donor fragment can participate in recombination and/or 
gene conversion with the target gene to correct or alter the nucleotide sequence.
Using a bi-functional oligomer with a 40-mer donor domain and a 30-mer TFO 
domain, correction of a single base pair mutation in the supF  reporter gene within a SV40 
vector in COS-7 cells was achieved [97]. Correction frequencies were in the range of 
0.1% with the full bi-functional molecule [97], Oligonucleotides consisting of either 
domain above or o f either domain substituted with heterologous sequences reduced 
activity by 10-fold or more [97]. The donor domain alone consistently did mediate some 
gene correction, as would be expected, based on the known ability o f DNA fragments to
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mediate some level o f recombination. However, there was a clear synergism due to 
combination with the TFO domain [97].
When measuring induced recombination in HeLa cell-free extracts, tethered and 
untethered TFOs and donors showed similar recombination frequencies [95]. This 
unlinking allowed for further exploration of the distance over which TFO binding could 
exert an effect on recombination by a short donor DNA molecule. A similar PNA was 
coupled with a 40-mer DNA donor molecule and induced recombination was measured in 
cell-free extracts [52], Correction o f a mutated reporter gene was found to be over 60- 
fold above background [52] when the PNA and donor were linked but was also 
demonstrated without covalent linkage.
Distance and TFO Effects
Given that in vivo there may not always be a TFO target site adjacent to the 
desired site o f gene modification, the distance constraints between the TFO binding site 
and the mutation site to be corrected by recombination were studied. The episomal target 
with the dual supF  genes described above had the upstream gene 4 base pairs from the 
TFO binding site and the downstream gene 29 base pairs from the site (Fig. 5A) [8], In 
the chromosomal TK assay, the TFO binding site was 0.8 kilo bases and 0.7 kilo bases 
away from the genes, respectively (Fig. 5B) [94], Recent work demonstrated in two 
episomal reporter systems that TFO-induced recombination was detectable at distances 
(between the TFO target site and the mutation to be corrected) from 24 base pairs to 750
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base pairs (Fig. 5C) [18], In both systems, recombination between the mutated gene on 
the episomal target and a wild-type donor fragment in the presence of TFO was measured 
[18]-
TFO Delivery
While the TFOs are active gene targeting molecules, delivery is a key factor in the 
biological activity of TFOs. Chromatinization of the DNA target, intracellular ion 
concentrations, and cytoplasmic versus nuclear separation of the TFO and DNA target 
are hurdles that have to be overcome in delivery o f a TFO into a cell. TFOs have been 
delivered into cells via lipid mediated TFO delivery [9, 98, 99] and electroporation [11, 
43], Cells have been directly injected [93] and mice have been intraperitoneally injected 
with TFOs [10]. Using cationic lipids as transfection reagents, compared to 
microinjection, showed much lower frequencies of recombination [93]. Cell membrane 
permeabilization by digitonin [47, 69] or streptolysin-0 [92] has also been used. 
Conjugation of TFOs and PNAs to a transport peptide derived from antennapedia has 
also been explored [100-102], Such conjugation increased mutation targeting frequencies 
in a chromosomal reporter gene by 20-fold compared to TFO alone, in a dose responsive 
manner [101]. This effect was target specific and not due to the antennapedia peptide 
alone [101]. Confocal microscopy demonstrated increased cellular uptake o f the 
conjugated TFO [101]. Taken together, these data suggest that TFO conjugation to 
antennapedia increases intranuclear delivery of TFOs.
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Specific Aims
Both purine and pyrimidine TFOs have been used to direct psoralen to a specific 
target, but only purine TFOs have been shown to induce genomic changes through repair 
and recombination when noncovalently bound to the duplex [9]. Previous work in our 
lab has largely focused on the purine motif, showing that purine TFOs are active in repair 
and recombination in cell-free extracts, in cell culture, and in mice [8, 10, 71, 92], 
Canonical nucleotides do not bind with high affinity in the pyrimidine motif under 
physiological conditions due to the requirement for cytosine protonation in the formation 
of Floogsteen bonds [103], In order to make pyrimidine TFOs a more effective tool, 
chemical modifications need to be used to enhance triplex stability in vivo. Modifications 
such as methylated cytosine, base substitutions, or sugar substitutions improve affinity in 
the pyrimidine motif and have been used for TFO-mediated-delivery o f DNA 
intercalators [29, 43],
In Chapter 2, a series of chemical modifications was examined for their ability to 
induce recombination and repair in the pyrimidine motif. The most effective of these 
modifications were the N3'->P5' bridging phosphoramidate (amidate) modification and 
the 5-(l-propynyl)-2'-deoxyuridine base substitution. Both showed enhanced in vitro 
TFO binding, increased repair in cell-free extracts, and increased recombination in 
episomal targets in an XPA-dependent manner. Several other chemical modifications 
showed enhanced binding but did not show increased repair or recombination.
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These chemically modified TFOs were compared to purine motif TFOs for their 
ability to induce recombination and repair in a single-copy genomic target. Previously, 
the ability o f TFOs to induce recombination between a target locus and a donor DNA was 
only demonstrated with multi-copy episomal targets in mammalian cells. In Chapter 3, 
we report that the amidate-modified TFO showed similar induced recombination 
frequencies compared to the purine TFO in a single-copy chromosomal target. The 
induced recombination was sequence-, target-, and dose-dependent with correction 
frequencies up to 0.1%.
The final goal of this work was to create altered helical structures and to examine 
where the incisions are made in repair of these structures. Previous work in the Glazer 
lab and work presented in Chapter 2 determined that triplex-induced repair and 
recombination requires XPA, a NER recognition factor [95, 104, 105], A 10 nucleotide 
TFO, conjugated to psoralen, and monoadducted to duplex DNA produces excision 
products, while a 30 nucleotide TFO does not produce excision products [106]. The 
nature of these excision products and the location of the incisions have not been 
previously evaluated. This idea is also consistent with the fact that the length of 
attachment o f some TFOs (i.e. TFOs 30 nucleotides long) exceeds the canonical excision 
span of NER. In order to understand the mechanism of triplex action and to elucidate the 
pathway by which triplexes promote repair and recombination, the incision sites in repair 
of the bulky adduct created by triplex binding need to be mapped. TFOs o f different 
lengths will be tested to determine the length limitation for NER to excise the triplex. In
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Chapter 4, altered helical structures using a variety of substrates (linear and plasmid) 
were evaluated in conjunction with TFOs to help develop an assay to understand the 
nature o f incisions made in repair of a triplex.
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Figure 1. Triplex-Binding Code and Orientation. (A) In the purine motif, triplex- 
forming oligonucleotides bind in an anti-parallel orientation via reverse Hoogsteen 
bonds. (B) In the pyrimidine motif, the third strand binds in a parallel orientation via 
Hoogsteen bonds. The canonical triplets are shown for each motif.
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Triplex Triplex Invasion Duplex Invasion Double Duplex Invasion 
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Figure 2. Peptide nucleic acid (PNA) binding to duplex DNA. (A) PNAs consisting 
o f cytidine-rich polypyrimidine sequences bind as third strands through Hoogsteen 
bonds. (B) PNAs can also bind as third strands in conjunction with a PNA that strand 
invades (binding via Watson-Crick base pairing to one strand of the duplex DNA). When 
the strand invading and triplex-forming strands are tethered together, they form a PNA 
clamp. Homopurine PNAs bind through single strand duplex invasion (C) or double 
strand (D) duplex invasion of the DNA. This figure was adapted from Nielson, P.E., 
(2001). Current Opinion in Biotechnology, 12: p. 16-20.
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Figure 3. TFO-induced gene modification. (A) TFO-directed mutagenesis. TFOs can 
be used for site-specific delivery o f DNA reactive conjugates such as psoralen. TFOs 
also induce mutations around the TFO binding site independent o f conjugation to reactive 
agents. (B) TFO-induced recombination. TFOs have been used in a variety of 
intramolecular and intermolecular targeting. Intramolecular targeting involves gene 
correction through recombination between tandem differentially mutated genes located 
on opposite sides o f a TFO binding site. Intermolecular targeting relies on either a 
tethered or untethered donor molecule for the wild-type correction of the mutation.
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Figure 4. Protocol for detecting chromosomal mutations in TFO treated mice.
Transgenic reporter mice containing multiple copies o f chromosomally integrated lambda 
supFGl (containing a triplex target site) and a control gene ell (lacking a triplex target 
site) were intraperitoneally (IP) injected with TFO for 5 consecutive days. Ten days later 
genomic DNA was isolated from a variety of tissues. Mutagenesis was detected by in 
vitro packaging of the phage followed by plating on a bacterial lawn (on plates containing 
IPTG and X-Gal). Mutant plaques were white while wild-type plaques were blue.
Mutant plaque DNA was isolated and sequenced.
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Figure 5. Reporter gene constructs for recombination. (A) Tandem supF  genes for 
psoralen-AG30 TFO targeting. Episomal target for transient transfection in COS-7 cells. 
The SupF gene upstream of TFO target site was mutated at base pair (bp) 163, the 
downstream SupF  gene was mutated at bp 115. (B) Dual thymidine kinase genes. A 
chromosomal target in mouse cells for induced recombination with two tandem mutated 
copies of the herpes simplex thymidine kinase (TK) gene. (C) The luciferase reporter 
construct used in the distance experiments. The TFO target site is 40 bp upstream of the 
gene start site and mutations in the firefly luciferase gene at the different distances are 
indicated (13 bp, 242 bp, 753 bp, 1255 bp).
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Introduction
TFOs provide potential tools for altering gene function by either repressing 
transcription, inhibiting DNA replication, or inducing site-specific mutagenesis and 
recombination [1-6]. TFOs bind in the major groove of DNA in a sequence-specific 
manner to polypurine/polypyrimidine sequences, in two distinct motifs [7-10]. TFOs in 
the purine motif bind anti-parallel to the purine strand of the duplex via reverse- 
Hoogsteen hydrogen bonds and TFOs in the pyrimidine motif bind in a parallel 
orientation via Hoogsteen bonds [7-10], The third-strand binding code specifies that in 
the purine motif G and A in the third strand bind to the duplex G and A, respectively; 
while in the pyrimidine motif C and T bind to the duplex G and A, respectively [11].
Binding affinity in the two motifs is differentially affected by pFI and ion 
concentrations. In the pyrimidine motif, the need for protonation o f cytosines at the N3 
position (favored at low pH) limits the binding affinity o f TFOs composed of unmodified 
DNA under physiological conditions [12]. In order to make TFOs more effective tools, 
chemical modifications have been developed to enhance third-strand binding under in 
vivo conditions. Base modifications such as 5-methyl-2'-deoxycytidine (5meC) and 5-(l- 
propynyl)-2'-deoxyuridine (pdU) and sugar modifications such as 2'-0-(2-aminoethyl)- 
ribose (2'-AE) substitution improve binding affinity and psoralen delivery in the 
pyrimidine motif [13, 14]. Pyrimidine TFOs with a N3'->P5' phosphoramidate (amidate) 
backbone (in which nitrogen replaces the bridging 3' oxygen of the diester) have also 
been shown to form stable triplexes at neutral pH [15].
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In addition, conjugation of intercalators such as pyrene and acridine to TFOs has 
been shown to further increase their biological activity [16]. Although purine TFOs 
consisting of standard DNA (except for 3'-end-capping [4, 17]) have been shown to be 
active in cells and animals [16-18], fewer strategies have been established for effective 
modification of purine TFOs. The most effective option that has been demonstrated is 
backbone substitution with N, N-diethylethylenediamine (DEED) intemucleoside 
linkages which reduce the Mg2+-dependence and enhance intracellular activity of 
polypurine TFOs [18].
Both purine and appropriately modified pyrimidine TFOs have been used to direct 
psoralen intercalation and photoadduct formation to specific sites in mammalian cells and 
yeast [16, 17, 19], In the absence of psoralen, however, only purine TFOs have been 
shown to induce genomic changes (either mutagenesis or recombination) via the effects 
o f third-strand binding alone [4]. Previous work has demonstrated that non-covalent 
triplexes formed by purine TFOs are active in stimulating repair and recombination in 
cell-free extracts, in cell culture, and even in mice [3,5, 20, 21]. Studies in human cell- 
free extracts and in DNA repair-deficient human cell lines have revealed the ability of 
non-covalent purine motif triplexes to provoke recombination in a manner dependent on 
the nucleotide excision repair (NER) pathway [4], ITowever, the ability o f non-covalent 
triplexes formed by pyrimidine TFOs to induce recombination has not been established.
In the work reported here, we sought to determine the extent to which triplexes 
formed by pyrimidine TFOs can stimulate recombination and repair. Because standard
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DNA TFOs bind poorly in the pyrimidine motif, we evaluated TFOs containing a series 
of modifications to determine which, if  any, are effective in provoking DNA metabolism 
via third-strand binding alone, in the absence o f a DNA-reactive conjugate. Interestingly, 
although several modifications did support high affinity binding under physiological 
conditions in vitro, only amidate and pdU-modified TFOs induced recombination in 
episomal targets in cells and repair in cell-free extracts. These results demonstrate that 
certain pyrimidine TFOs can provoke recombination without the need for covalent 
damage to the DNA. Because pyrimidine triplexes are favored at A:T bp-rich sites (in 
contrast to purine triplexes, which are favored at G:C rich sites), these findings increase 
the number o f potential genomic target sites suitable for modification by non-covalent 
triplexes. In addition, we propose a model in which TFO sugar substitution at the 2' 
position may influence the extent to which the resulting triplex can provoke DNA 
metabolism, with reference to NMR studies showing that 2' substitution of the TFO 
influences the degree of structural distortion of the duplex to which the TFO is bound 
[22],
Materials and Methods 
Oligonucleotides and Vectors
Oligonucleotides were obtained from Transgenomic (amidatel8), Gilead Sciences 
and Eurogentec (G3pUmC18), Oligos Etc. (G3TmC18, 2 '-0-M el8), Proligo (LNA18, 
LNAcontrol) and Eurogentec (LNA18), Eurogentec (UmCcontrol), Gene Tools
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(morphl8), Midland Certified Reagents Company (AG30, SCR30, MIX30, as51), 
Rowshon Alam and Michael Seidman (2-AE), Chip Greaves and Dan Weeks (DEED), 
and Keck Oligonucleotide Synthesis Facility (Yale University) (AG19, DNA18). Duplex 
target oligonucleotides (G3Y, G3R) were synthesized by Oligos Etc. When the chemical 
modification did not provide protection against exonuclease degradation, which is 
necessary for cell targeting experiments, 3'-ends were synthesized to contain a 3' 
propylamine group, using the C3 amino-CPG from Glen Research. The following 
oligonucleotides contain a 3' propylamine group: G3TmC18, G3pUmC18, AG30,
SCR30, and MIX30. Three terminal phosphorothioate linkages were synthesized on the 
3'-end of 2 '-0-M el8 and as51 has terminal phosphorothioate linkages on both ends. 
Pyrimidine TFO sequences and modifications are listed in Fig. 1. The sequences for the 
control oligonucleotides are as follows: AG30, 5'AGGAAGGGGG GGGTGGTGGG 
GGAGGGGGAG 3'; SCR30, 5’ GGAGGAGTGG AGGGGAGTGA GGGGGGGGGG 
3’; MIX30, 5' AGTCAGTCAG TCAGTCAGTC AGTCAGTCAG 3'; UmCcontrol, 5’ 
cucucucucuuuuuuu 3' (c = 5meC, u = pdU); LNAcontrol, 5' TtTTCtTTTtTCTtTTCt 3'
(t = LNA); AG19, 5'AGGAAGGGGG GGGTGGTGGG 3'; DNA 18, 5' TTTTCTTTTT 
TCTTTTCT 3'. And the single-stranded donor, as51, had the sequence: 5' 
TGGTAAAGCC ACCATGGAAG ACGCCAAAAA CAT A A AGAAA 
GGCCCGGCGCC 3'.
The pSupFTC18 shuttle vector, derived from pSP189 [23], carries two copies of 
the supF  gene, each with a distinct mutation, flanking an 18-bp A-rich
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homopurine/homopyrimidine target site (the T C I8 site from pLSG3 [13]). These 
mutations were created using the QuikChange Site-Directed Mutagenesis Kit 
(Stratagene). These mutations result in inactive tRNAs which lack the ability to suppress 
the amber mutation in the lacZ gene in MBM7070 E. coli which are used as indicator 
hosts for this recombination assay [24],
The plucTC18 vector was derived from a plasmid constructed by subcloning the 
firefly luciferase gene Fluc+ (pGL3-Basic Vector, Promega) into pcDNA5/FRT 
(Invitrogen) [25]. The TCI 8 target site was inserted 40 bp upstream of the Fluc+ start 
site. Site-specific mutagenesis was used to create a stop codon at bp 13 downstream from 
the start codon.
The pRLTC18 vector was constructed by adding the TFO target site (the T C I8 
site from pLSG3 [13]) into the multiple cloning region o f the pRL-CMV vector 
(Promega).
Third-strand binding assays
Third-strand binding was measured using gel mobility shift assays under native 
conditions. Two complementary 30-mers (G3Y, G3R) containing the TC I8 target from 
pLSG3 (representing bp 76 to 105) were synthesized. Duplex DNA was prepared by 
mixing 1000 pmol of each 30-mer together with 50 mM NaCl and incubating at 85°C for 
20 minutes and cooling to room temperature before end-labeling with T4 polynucleotide 
kinase (New England BioLabs) and [y-32P]ATP (Amersham Biosciences). Duplex was 
gel purified, electroeluted, and filtered by Centricon (Millipore). A fixed concentration
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of duplex at 5 x 10"8 M was added to binding reactions with increasing concentrations of 
oligonucleotides in 20 pi of 10 mM Tris (pH 7.2) and selected concentrations of MgCl2 
(0.1 mM or 10 mM) and KC1 (0 mM or 140 mM). Binding for full DEED 18 was carried 
out at pH 7.6 with the addition of 1 mM spermine. Binding assays were also carried out 
at pH 5.4, in which case 40 mM Tris-acetic acid was substituted for Tris base at pH 5.4. 
Samples were incubated at 37°C for 16 hours unless otherwise specified.
Samples bound at pH 7.2 were loaded onto 15% polyacrylamide gels 
[acrylamide/bisacrylamide (19:1)] containing 17.8 mM Tris and 17.8 mM boric acid (pH 
7.2) and 10 mM MgCF and the gels were run in the same concentration of Tris-boric acid 
and MgCl2  at 60 V for 6  hours at 23°C. For samples bound at pH 5.4, 15% 
polyacrylamide gels containing 40 mM Tris-acetate and 10 mM MgCl2  were used and 
gels were run in buffers o f the same concentration of Tris-acetate and MgCF at 60 V for 
6  hours at 23°C.
Shuttle vector recombination assay
Monkey COS-7 cells were obtained from ATCC (1651-CRL) and grown in 
DMEM/10% fetal bovine serum (FBS) (Gibco). Cells were grown to 50-70% confluency 
and cell transfection was performed with GenePORTER2 (Gene Therapy Systems, Inc.). 
Cells were transfected with 1 pg o f pSupFTC18 followed 24 hours later by a second, 
separate transfection with 1 pg of oligonucleotide. Cells were harvested at 48 hours after 
oligonucleotide transfection and shuttle vector DNA was isolated by a modified alkaline
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lysis procedure, as previously described [6 ], Vector samples were used to transform 
indicator bacteria (MBM7070 [lacZ(Am)] [23]) by electroporation (Bio-Rad gene pulser; 
settings: 25 pF, 250 W, and 1800 V; 0.1 cm electrode gap cuvette), and colonies were 
screened for supF  function by growth on plates supplemented with 75 pg/ml ampicillin, 
210 pg/ml 5'-bromo-4-chloro-3-indolyl-(3-D-galactopyranoside (X-Gal), and 200 pg/ml 
IPTG (isopropyl-P-D-thiogalactopyranoside). Recombination events were indicated by 
wild-type blue colonies in a background of white colonies.
CHO cell transfection and luciferase assay
CHO cells were obtained from Invitrogen and grown in F12/10% FBS (Gibco) 
supplemented with 2 mM L-glutamine (Gibco) and 100 pg/mL Zeocin (Invitrogen).
CHO cells were transfected and the luciferase activity was assayed as previously 
described [25]. Briefly, 24 hours prior to transfection, 12-well plates were seeded with 
5 x 104 cells/well. plucTC18 was preincubated overnight with as51 (an oligonucleotide 
containing the wild-type luciferase sequence for the mutated region) and the TFO to be 
tested with 10 mM MgCF and 10 mM Tris pH 7.2 at 37°C. Cells were transfected with 
GenePORTER2 as described above. Each transfection delivered 0.3 pg of plasmid, 
donor, and TFO per well. Cells were collected 48 hours post-transfection by rinsing 
twice with PBS followed by lysis with lx  Passive Lysis Buffer (Promega). Luciferase 
activity was measured using the Promega Dual Luciferase Kit and only the LAR II
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substrate. The total protein in the cell lysate was determined via Bradford protein assay 
[26].
In vitro repair synthesis assay
Repair reactions were carried out as described [27], with several modifications. 
HeLaScribe Nuclear Extract in vitro Transcription Grade (Promega) was used. The 
pRLTC18 plasmid (500 ng) containing the T C I8  target sequence was preincubated with 
1 pM TFO (37°C, 18 hours, 10 mM Tris, pH 7.2, 10 mM MgCU). As a positive control, 
one sample was incubated with sterile water in place of oligonucleotide, this sample was 
then damaged by UVC radiation treatment (2 inches, 30 seconds). The DNA was added 
to HeLa cell-free extracts with [a-3 2 P]dCTP (Amersham Biosciences) and supplemented 
as previously described [27], Samples were incubated for 3 hours at 30°C and the 
reactions were stopped as previously described [27]. Substrate plasmid DNAs were 
isolated from the reaction by phenol/chloroform/iso-amyl alcohol extraction and ethanol 
precipitation. The isolated vector DNAs were linearized by Xho I digestion and the 
samples were analyzed by gel electrophoresis. DNA repair synthesis was quantified by 
measure of [a-3 2 P]dCTP incorporation using a phosphorimager (Storm 860, Molecular 
Dynamics, Amersham Pharmacia Biotech). The quantified value of the UVC treated 
sample was set to 1 0 0 % and used to normalize the measurements of the other samples. 
Shuttle vector assay in repair-deficient and corrected cells
XP12BE cells (deficient in the nucleotide excision repair factor, XPA) were 
obtained from Coriell Cell Repositories (GM04429) and grown in MEM/10% FBS
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(Gibco). The shuttle vector recombination assay was performed as described above 
except that in some cases the cells were also transfected with 1 pg of a plasmid 
containing XPA cDNA (XPA cDNA with a His tag on the C-terminus cloned into the 
multiple cloning site of pcDNA3.1 (Invitrogen)) at the same time the cells were 
transfected with the psupTC18. XPA expression was verified by Western blot. Briefly, 
cells were lysed (at 48 and 72 hours post-transfection) with RIPA buffer (150 mM NaCl, 
0.1% SDS) and 100 pg of total protein per sample was resolved on 12% SDS/PAGE gels. 
Proteins were detected by standard immunoblot procedures using XPA [28] and tubulin 
(clone B-5-1-2; Sigma) primary antibodies.
Serum stability assay
Each oligonucleotide was 5'-end-labeled at a concentration of 1 pM with 
[y-3 2 P]ATP using T4 polynucleotide kinase (New England BioLabs) for 1 hour, followed 
by heat inactivation for 20 minutes at 70°C. 5 pi of end-labeled oligonucleotide were 
added to 100 pi of FBS (Gibco) and incubated at 37°C. Aliquots were removed at 0 to 24 
hours and added to an equal volume of formamide dye, before being run on a 2 0 % 
denaturing polyacrylamide gel. Visualization and quantification o f intact oligonucleotide 
was done using a phosphorimager.
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Results
TFO target site and oligonucleotide modifications
To examine the ability of triplexes formed in the pyrimidine, parallel motif to 
induce recombination and repair, we evaluated a series of chemically modified 
pyrimidine TFOs each designed to bind to an 18 bp A-rich duplex target site (Fig. 1).
The modifications included amidate and DEED internucleoside linkages and 5meC and 
pdU base substitutions. Sugar modifications included 2 '-0 , 4'-C-methylene bridged or 
locked nucleic acid (LNA), 2'-0-methyl-ribose (2'-0-Me), and 2'-AE substitutions. 
Morpholino (morph) TFOs consist of both sugar and backbone changes (Fig. 1).
We chose these modifications because either they have been shown to enhance 
intracellular delivery of psoralen conjugates to target genes [amidate [29-33], DEED 
[18], 5meC [13, 34], pdU [13, 34, 35], 2'-0-M e [14], and 2'-AE [14]] or they have been 
found to provide enhanced third-strand binding in vitro [LNA [36-38] and morpholino 
[39, 40]]. In the case of the DEED modification, enhanced chromosome targeting has 
been demonstrated only in the purine motif. However, the ability o f the DEED 
internucleoside substitution to confer a potentially advantageous positive charge on the 
TFO prompted us to consider pyrimidine TFOs with either full or partial DEED 
modifications.
Unless otherwise specified, all TFOs contained phosphodiester backbones. In 
some cases all nucleotides were modified in a given TFO while in other cases only 
selected ones were modified, as indicated (Fig. 1). The C’s in G3TmC18, G3pUmC18,
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2'-0-M el8, and 2'-AE18 were substituted with 5meC, because this modification has been 
shown to enhance third-strand binding at physiological pH [41, 42] and U’s in 2'-AE18 
contained 5-methyl-2'-deoxyuridine modifications. Nucleotides in2'-AE18 not 
containing the 2'-AE modification were synthesized to contain 2'-0-M e modifications.
In vitro binding measurements
The binding affinities of TFOs with the modifications described above were 
compared under a series of conditions as determined by gel mobility shift assays in non­
denaturing gels. Binding was quantified and equilibrium dissociation constants (K fs,
representing TFO concentrations yielding half-maximal binding) were determined.
2+ _|_
Because stable triplex formation is dependent on Mg and sensitive to K [43, 44], we 
tested binding in either 0.1 or 10 mM MgCF and either 0 or 140 mM KC1 (both 
conditions at pH 7.2). In recognition of the possible pH dependence o f binding by certain 
TFOs, we also tested binding at pH 5.4 (in 10 mM MgCF and without KC1).
Under conditions where the minimally modified TFO, G3TmC18, formed 
triplexes (pH 5.4, 10 mM MgCF, 0 mM KC1), all of the chemically modified TFOs 
formed triplexes (Fig. 2). However, there was a range of binding affinities (Fig. 2 and 
Table 1). The best binding was seen with the amidate, LNA, 2'-AE, pdU, and 2'-0-M e- 
modified oligonucleotides, with K fs  o f 2.8xlO"10, 3.0x10"’°, 4xlO"10, 4.5xlO"10, and 
4.6xlO" 10 M, respectively (Fig. 2 and Table 1). G3TmC18, m orphl8 , and partially 
modified DEED oligonucleotides showed lower binding affinities, and the full DEED 18 
showed the lowest binding affinity (Fig. 2 and Table 1).
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At neutral pH with 10 mM MgCh, the 2'-0-M e, LNA, 2'-AE, and amidate - 
modified TFOs showed strong binding with Kd’s of 1.5xlO'10, 2.7xlO'10, 6 .0xl0 '10, and 
8.0xl0 ' 10 M, respectively (Fig. 2 and Table 1). The pdU and 5meC-modified TFOs 
showed approximately 10-fold weaker binding and the morpholino-modified TFO 
showed 1000-fold weaker binding. Neither of the DEED-modified oligonucleotides 
(partial or full) showed any binding at neutral pH.
Under physiological conditions (pH 7.2, 0.1 mM MgCL, and 140 mM KC1), the 
amidate, 2'-AE, LNA, and pdU-modified TFOs showed the strongest binding with Kd’s 
of 1.0x1 O'8, 2.0xl0‘8, 2 .5xl0 '8, and 9.0xl0 ' 8 M, respectively. G3TmC18 showed slightly 
weaker binding, and the morpholino and the 2'-0-Me-modified TFOs showed even 
weaker binding. The DEED-modified TFOs showed no detectable binding under these 
conditions.
TFO-induced recombination in COS-7 cells
To test triplex-induced recombination by pyrimidine TFOs, we constructed a 
SV40-based shuttle vector similar to pSupFAR used in previous work to test purine TFOs 
[20]. However, in this case, we designed the vector to contain the 18 bp A-rich target site 
used in the binding assays above. This site is inserted between two copies of the supF  
gene, each with an inactivating point mutation, at bp 163 in the upstream gene and at bp 
115 in the downstream gene (Fig. 3A). The 5' mutation is 33 bp from the beginning of 
the TFO binding site while the 3' mutation is 24 bp away from the end of the site. 
Recombination between the two genes can generate a functional supF  gene, which can be
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scored upon shuttle vector transformation into indicator bacteria following vector DNA 
rescue from the COS-7 cells.
The plasmid vector was pre-transfected into the COS-7 cells to establish the 
episomal target in these cells. One day later, the cells were transfected with the TFOs 
and maintained in culture for 48 hours to allow for triplex formation and possible induced 
recombination. As a negative control to establish the background frequency of 
recombination in this assay, we included in each experiment cells transfected with vector 
but mock transfected the next day without TFO. The vector DNAs were harvested from 
the cells and analyzed for recombination events (Fig. 3B). The results were normalized 
between experiments by comparison to the plasmid only (no oligonucleotide) background 
and presented as recombination frequency. Transfection o f cells with the amidate 18 and 
G3pUmC18 TFOs gave the highest levels of induced recombination, at 0.37% and
0.31%, respectively; whereas G3TmC18, 2'-AE18, and m orphl8  gave lower frequencies 
of 0.14%, 0.14%, and 0.13%, respectively. The 2'-0-M e, TNA, and DEED TFOs had 
minimal effects over background. The control TFOs, UmCcontrol, LNAcontrol, AG30, 
SCR30, and MIX30 showed little effect over background.
To further control for sequence specificity, we tested induced recombination by 
the amidate 18 and G3pUmC18 TFOs using a different shuttle vector, pSupFAR, as a 
target in the cells. pSupFAR contains two mutant supF  genes flanking a 30 bp G-rich 
polypurine target site suitable for triplex formation in the purine motif [3]. In previous 
work, we have shown that a G-rich TFO, AG30, can bind with high affinity to the third-
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strand binding site in pSupFAR [3]. AG30 shows no detectable binding to the A-rich 
polypurine site found in pSupFTC18, and conversely, TC-rich pyrimidine TFOs show no 
binding to the G-rich site in pSupFAR (data not shown). We found that while 
transfection of am idatel8  and G3pUmC18 into COS-7 cells can induce recombination in 
pSupFTC18, neither has an effect on recombination in pSupFAR in the same cell assay 
(nor do any of the other modified pyrimidine TFOs tested) (Fig. 4). In contrast, AG30 
can induce recombination in pSupFAR in COS-7 cells but has no effect on recombination 
in pSupFTC18 (Fig. 4). Hence, the effects of the am idatel8 , G3pUmC18, and AG30 
TFOs are sequence-specific, based on both oligonucleotide and target site controls. 
TFO-induced recombination in CHO cells
To test pyrimidine induced recombination in a different episomal target, we 
constructed the plucTCl 8  plasmid, which is a vector containing a pyrimidine TFO target 
adjacent to a mutated firefly luciferase reporter gene, similar to a vector used in previous 
work studying targeting in the purine motif [25], The TFO binding site is 40 bp upstream 
from the start site of the luciferase gene, and a nonsense mutation that inactivates the 
luciferase gene is 13 bp downstream from the start site. In this assay, recombination 
induced by TFO binding occurs between the plasmid and a separate donor 
oligonucleotide (a 51 -mer) containing the wild-type luciferase sequence in the region of 
the mutation. The amidate 18 was found to induce recombination at a frequency o f 0.11% 
(Fig. 5B), whereas the 2'-0-M e and 2'-AE-modified TFOs showed minimal levels of 
induced recombination above background.
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Pyrimidine TFO-induced repair in HeLa cell-free extracts
Because previous work had shown a correlation between the ability of purine 
TFOs to induce recombination and the ability o f the triplexes they form to induce repair, 
we assayed for induced repair synthesis in FleLa cell-free extracts on plasmid substrates 
containing pyrimidine m otif triplexes. The substrate for DNA repair was a plasmid 
incubated in the presence or absence of TFO. The amount of DNA repair-associated 
synthesis was measured based on the level o f incorporation of [a-3 2 P]dCTP into the 
plasmid. This is a well-established assay for measuring repair provoked by a variety of 
DNA lesions [45-47]. Am idatel8  and G3pUmC18 showed the highest level of induced 
repair activity at 42% and 6 6 %, respectively, as compared to UVC damage set at 100% 
activity (Fig. 6 A and 6 B). G3TmC18 and LNA18 produced lower repair activity (Fig.
6 A and 6 B).
Pole o f  nucleotide excision repair in induced recombination
To determine if the induced recombination in cells by the amidate 18 TFO is due 
to the NER pathway, a shuttle vector assay similar to that used in COS-7 cells, above, 
was performed in XP12BE cells. These cells are SV40 transformed fibroblasts isolated 
from a patient lacking the Xeroderma Pigmentosum, complementation group A protein 
(XPA, a recognition protein in the NER pathway). The amidatel 8  TFO was unable to 
induce recombination in XP12BE cells (Fig. 6 C). Elowever, with the expression of XPA 
cDNA, induced recombination by amidatel 8  was detected (Fig. 6 C). The expression of 
XPA in the cDNA-transfected cells was confirmed by Western blot (Fig. 6 D).
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Nuclease resistance o f  pyrimidine TFOs
To test the possibility that differences in resistance to nucleases of the various 
TFOs could be responsible for the observed differences in induced recombination 
frequencies, we tested the stability of selected TFOs in serum. The 5'-end-labeled TFOs 
were added to FBS and aliquots were removed at time points from 0 to 24 hours to 
measure the quantity of full-length oligonucleotide by gel electrophoresis and 
autoradiography. After 1 hour in serum, most o f the chemically modified pyrimidine 
TFOs were intact, except for the unmodified-TFO DNA18 and the 5meC-modified TFO 
G3TmC18 (Fig. 7). After 3 hours, the am idatel8 , TNA18, 2 '-0-M el8, 2'-AE18, and the 
G-rich TFOs all showed greater than 50% remaining intact. The G3pUmC18 TFO 
showed around 36% oligonucleotide intact at 3 hours. By 6  hours only the 2'-AE18 and 
the amidatel8  pyrimidine motif TFOs showed greater than 50% intact; the G3pUmC18 
TFO showed about 25% intact. In all cases, less than 10% of the pyrimidine TFOs 
tested remained intact at 12 hours. Interestingly, two G-rich TFOs, AG30 and AG19 
showed higher levels of nuclease resistance, with greater than 50% oligonucleotide 
remaining intact at 24 hours (Fig. 7) and persisting at this level even to 72 hours (data not 
shown). This serum stability shown by the G-rich TFOs may, in part, account for their 
documented effectiveness for gene targeting in vivo following systemic administration in 
mice [5].
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Discussion
In the work reported here, we tested a series of TFOs with selected chemical 
modifications for their ability to bind as third strands in the pyrimidine motif under a 
variety of in vitro conditions, for their ability to induce recombination in two different 
cell-based episomal targeting assays, and for their ability to induce repair in cell-free 
extracts. We found that high affinity in vitro binding was necessary but not sufficient for 
increased intracellular activity. Certain modifications that provide for enhanced in vitro 
binding were only minimally effective at increasing the ability o f TFOs to induce 
recombination in cells or to stimulate repair in cell-free extracts, while others (amidate 18 
and G3pUmC18) stood out in the initial screen and their activity held up under close 
evaluation (showing both high third-strand binding affinity and effective intracellular 
activity). These differences cannot simply be attributed to differential nuclease 
resistance.
The modified TFOs with the highest binding affinities under physiological 
conditions in vitro (low Mg2+, high K+, and neutral pH) were amidate 18, G3pUmC18, 2'- 
AE18, and LNA18. O f these, only the amidate and pdU-modified TFOs mediated 
increases in recombination frequencies over background, 3.4 and 2.8-fold, respectively. 
The recombination frequencies in the COS-7 episomal shuttle vector assay produced by 
am idatel8  (0.37%) and G3pUmC18 (0.31%) are comparable to the recombination 
frequency induced by AG30 in a similar shuttle vector assay (0.40%). These 
recombination frequencies are based on targeting an episomal not a chromosomal target.
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Transfection o f the episomal target 24 hours prior to oligonucleotide transfection allowed 
for chromatin assembly on the target plasmid [48], In the purine motif, similar 
mutagenesis and recombination frequencies have been established in episomal and 
chromosomal targets using G-rich TFOs with both targets [4, 6 , 17, 49].
Using a second episomal targeting assay based on intermolecular recombination 
in a luciferase reporter gene, similar results were seen with the amidate 18 TFO, with a 
recombination frequency o f 0.11% (which is a 48-fold induction o f recombination 
compared to recombination by donor DNA alone in this assay). Thus, in two distinct 
episomal targeting systems in cells, the amidate 18 TFO was seen to induce 
recombination in the absence of covalent adduct formation.
Additionally, the amidatel 8  and the G3pUmC18 TFOs induced repair in cell-free 
extracts. In cells, the induction of recombination in the shuttle vector assay by 
amidate 18 was found to be dependent on XPA, consistent with the in vitro repair results 
and further suggesting that triplexes formed by amidate 18 induce recombination in a 
repair-dependent manner.
Hence, while several of the chemically modified TFOs in the pyrimidine motif 
were found to bind well as third strands under physiologic conditions in vitro, only the 
amidate 18 and G3pUmC18 TFOs were seen to induce recombination and repair. One 
explanation consistent with our results would be that the triplexes formed by the 2'-AE 
and LNA-modified TFOs are less effective at provoking DNA repair and thereby less 
effective at inducing recombination. Our prior work with purine motif TFOs indicated
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that triplexes can be recognized as “lesions” in the DNA by factors in the NER pathway, 
leading to induced repair and recombination [4, 20, 27], Our current results suggest that 
the same is true for the pyrimidine motif triplexes formed by amidatel 8  or G3pUmC18 
TFOs.
Conceptually, this recognition is likely to result from helical alterations caused by 
triplex formation [50], Interestingly, Asensio et al. [22] found in an NMR-based 
structural analysis o f pyrimidine motif triplexes that the degree of duplex helical 
distortion can be influenced by substitutions at the 2'-position of the ribose on the TFO. 
Comparing TFOs with 2'-deoxy (DNA), 2'-OH (RNA), and 2'-0-methyl (2'-0-Me) ribose 
moieties, they found that the relative degrees o f distortion were: DNA > RNA > 2'-0-M e. 
Hence, RNA-like substitution at the 2'-position in the TFO, which tends to promote a C3- 
endo sugar conformation [51], appears to reduce the helical distortion that occurs upon 
third-strand binding.
The TFOs showing the highest levels o f induced recombination were amidatel 8  
and G3pUmC18 in the pyrimidine motif and AG30 in the purine motif. All of these 
contain DNA-like deoxyribose. In contrast, the 2'-AE18 and LNA18 TFOs have RNA- 
like 2'-substituted sugars. In fact, the LNA 2' substitution (consisting of the 2 '-0, 4'-C- 
methylene bridge) locks the ribose into the RNA-like C3-endo conformation [52], This is 
proposed to be an advantage for triplex formation because it may serve to pre-organize 
the TFO into a uniform conformation favorable to third-strand binding [52], but it may 
also serve to minimize the resulting helical distortion. Therefore, based on this model, it
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is possible that the am idatel8 , G3pUmC18, and AG30 TFOs may create triplexes that are 
more distorting than those produced by the 2'-AE18 and LNA18, resulting in an 
increased ability of the resulting triplexes to provoke DNA repair (as shown) and thereby 
stimulate recombination.
In conclusion, the work reported here demonstrates that non-covalent pyrimidine 
TFOs, when appropriately modified, can mediate high affinity binding, induction of 
recombination in cells, and induction of repair in cell-free extracts, at levels similar to 
those seen with G-rich purine TFOs at their respective target sites. These results expand 
the number of possible reagents for targeted genome modification.
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Figures and Tables
Table 1. Binding of chem ically modified pyrim idine oligonucleotides to an 
18 bp A-rich site/'
oligonucleotide
pH 5.4 
10 mM  M gC l2 
0 mM  KC1
pH 7.2 
10 m M  M gC l2 
0 mM  KC1
pH 7.2 
0.1 mM M gCl, 
140 mM K C f
am idatelS 2.8 x 10 10 8.0 x 10 10 1.0 x 10 s
pDEED18 3.0 x 10 s none none
full DEED 18 1.0 x 10-B none1’ none
G3TmC18 3.0 x 1 0 9 7.0 x 1 0 9 3.0 x 1 0 7
G3pUmC18 4.5 x 1 0 1() 7.0 x lO'9 9.0 x 10 s
2 '-0 -M e l8 4.6 x 10 10 1.5 x 10 19 8.0 x 1 0 3
2'-AE18 4.0 x 10 10 6.0 x 10 10 2.0 x 1 0 8
LNA18 3.0 x  10-10 2.7 x 10 10 2 .5 x 1 0 8
morph 18r 3.0 x 10 s 3.5 x 1 0 6 5.1 x 1 0 6
a Binding affinities were calculated as equilibrium  dissociation constants 
(K s) under the indicated conditions, as determ ined by gel m obility shift 
assay under non-denaturing conditions. Kd values are given in molarity. 
B inding was done for 16 hours at 37"C unless otherw ise specified.
11 Binding was done at pH 7.6 with 1 m M  sperm ine.
1 Binding was done at 23°C.
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Duplex target and oligonucleotides
G3Y 5'tcgaggTCTTTTCTTTTTTCTTTTagggggg3' 
G3R 3 'agctccAGAAAAGAAAAAAGAAAAtccccccS'
amidatel8 3 ' tcttttcttttttctttt 5
pDEED18 3 ' TcTTTTcTTTTTtCTTTt 5
full DEED18 3 ' tcttttcttttttctttt 5
G3TmC18 3 ' TcTTTTcTTTTTTcTTTT 5
G3pUmC18 3 ' ucuuuucuuuuuucuuuu 5
LNA18 3 * TcTtTtCtTtTtTcTtTt 5
2'-0-Mel8 3 ' tcttttcttttttctttt 5
2'-AE18 3 ' UcuuuUCUUUUUUCUUUU 5
morphl8 3 ' tcttttcttttttctttt 5
Figure 1A. Duplex target and oligonucleotide modifications. The third-strand 
binding site is indicated in capital letters in the duplex (G3Y/G3R) used for binding 
studies. For the oligonucleotides, lower case letters indicate modified nucleotides with 
the specific chemistry as indicated in the name of the oligonucleotide. Upper case letters 
indicate unmodified nucleotides. All internucleoside linkages in am idatel8  are N3'->P5' 
phosphoramidate (amidate)-modified. N, N-diethylethylenediamine (DEED)-modified 
nucleotides are present in partial DEED (pDEED18) and full DEED 18 as indicated. 
G3TmC18 contains 5-methyl-2'-deoxycytidines (5meC) in place of cytidines.
G3pUmC18 contains 5meC-modifications on all cytidines and all thymines are replaced 
by 5-(l-propynyl)-2'-deoxyuridines (pdU). LNA18 contains unmodified nucleotides 
alternating with 2'-0, 4'-C-methylene bridged or locked nucleic acid (LNA)-modified 
nucleotides. 2 '-0-M el8 contains 2'-0-methyl-ribose (2'-0-Me)-modified nucleotides and 
all cytidines have 5meC-modifications. 2'-AE18 contains 2'-0-(2-aminoethyl)-ribose (2'- 
AE)-modified nucleotides at the four lower case letter positions, while the upper case 
positions have 2'-0-Me-modifications and all positions also have either 5meC- 
modifications or 5-methyl-2'-deoxyuridine modifications. All nucleotides in m orphl8  
are morpholino (morph)-modified.
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Chemical Structures
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Figure IB. Structures of the chemical modifications. N3'->P5' phosphoramidate 
(amidate); N, N-diethylethylenediamine (DEED); 5-methyl-2'-deoxycytidine (5meC); 5- 
(l-propynyl)-2'-deoxyuridine (pdU); 2 '-0 , 4'-C-methylene bridged or locked nucleic acid 
(LNA); 2'-0-methyl-ribose (2'-0-Me); 2'-0-(2-aminoethyl)-ribose (2'-AE); morpholino 
(morph).
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Oligonucleotide Concentration (M)





ft * t ft
G3TmC18 L» * * ***' w
G3pUmC18 Mt* u t a w , u . «
2'-0-Mel8
m  m V* «s* W igt «■»«*
2'-AE18 •* **
w-“  Ansta# k s m m *  tmt -
LNA18 _  mm
morphl8
m ■ - — - ft* ,, . . M W
^  pH 5 g  pH 7.2 q  pH 7.2
10 mM MgCl2 10 mM MgCl2 0.1 mM MgCl2
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Figure 2. Third-strand binding under selected conditions as determined by gel 
mobility shift analysis. The first lane in each panel contains duplex alone (0 
concentration of TFO), the second lane contains 10' 5 M oligonucleotide, and each 
subsequent column contains a ten-fold dilution. Third-strand binding conditions: (A) pH 
5.4, 10 mM MgCl2, and 0 mM KC1; (B) pH 7.2, 10 mM MgCl2, and 0 mM KC1; (C) pH 
7.2, 0.1 mM MgCl2, and 140 mM KC1. The bands o f reduced mobility relative to the 
duplex alone represent triplex formation.
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Recombination Construct
3' TCTTTTCTTTTTTCTTTT 5'3 ' CACCACCCCAA A  GCCGGCTCTAGAAAA<3AAAAAAGAAAATCTAGACACCA C  CTTCCAAGCTTA 5'
5' GTGGTGGGGTT T-- CGGCCGAGATCTTTTCTTTTTTCTTTTAGATCTGTGGT--- A ---GAAGGTTCGAAT 3 '
pBR327
amp
SupF163 163 115 SupF115
pSupF T C 18 pBR327origin
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Figure 3. Induced recombination mediated by pyrimidine TFOs. Schematic 
representation of the pSupFTC18 vector. This SV40-based vector contains two mutant 
supF genes in tandem. The upstream mutant supF  gene, supF163, contains a C-to-T 
point mutation at nucleotide position 163. The downstream mutant supF  gene, supF115, 
contains a G-to-A point mutation at nucleotide position 115. In between the two mutant 
supF  genes is an 18 bp A-T rich homopurine/homopyrimidine target site. The chemically 
modified oligonucleotides described in Fig. 1A were designed to bind to this target 
sequence. (B) Triplex-induced recombination in COS-7 cells. The plasmid described in 
(A) was pre-transfected into COS-7 cells followed one day later by transfection of the 
indicated oligonucleotides or mock transfection. After 48 hours, shuttle vector DNA was 
isolated and transformed into indicator bacteria to analyze supF gene function and allow 
quantification of recombination events. Percent recombination was calculated by the 
ratio of the number of blue colonies to total colonies between cells transfected with the 
modified TFOs and mock-transfected cells.
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Figure 4. Sequence-specificity of the TFO-induced recombination. (A) Triplex- 
induced recombination with a pyrimidine motif target. Cells pre-transfected with the 
dual supF plasmid containing the 18 bp A-T rich site, pSupFTC18, were transfected the 
next day with lipid reagent alone or with the indicated TFOs. AG30 and SCR30 are G- 
rich TFOs and MIX30 has a mixed sequence. Shuttle vector rescue and analysis were 
performed as for Fig. 3. (B) Triplex-induced recombination with a purine motif target. 
Cells pre-transfected with a dual supF  plasmid containing a 30 bp G-rich site, pSupFAR, 
were transfected one day later with lipid reagent alone or with the indicated TFOs. 
Analysis of recombination events was performed as above. Amidate 18 and G3pUmC18 
bind with high affinity to the A-rich target site in the intergenic region in pSupFTCl 8  but 
not to the G-rich site in pSupFAR. AG30 binds well to the site in pSupFAR but not to 
that in pSupFTC 18.
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Figure 5. Intermolecular induced recombination mediated by pyrimidine TFOs.
(A) Schematic o f the plucTC18 construct. The plasmid contains the pyrimidine triplex 
binding site located 40 bp upstream of the start codon for the firefly luciferase gene. The 
luciferase gene has a nonsense mutation at 13 bp downstream from the start codon. (B) 
Percent recombination in CHO cells. Plasmid, TFO, and the donor oligonucleotide 
(as51) were co-transfected into CHO cells. After 48 hours, cells were lysed and 
recombination was measured based on relative light units and normalized to protein.
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Figure 6. Pyrimidine motif TFOs and DNA repair. (A) Pyrimidine triplex-induced 
DNA repair in HeLa cell-free extracts. TFOs and plasmids were co-incubated in HeLa 
cell-free extracts supplemented with [a-3 2 P]dCTP. Induced DNA repair synthesis was 
measured by visualization and quantification of incorporation o f [a-3 2 P]dCTP into the 
plasmid. As a positive control, plasmid alone was treated with UVC irradiation. (B) 
Quantification of induced repair as measured by [a-3 2 P]dCTP incorporation in (A); 
normalized to UVC-treated plasmid representing 100% repair activity. (C) Dependence 
of triplex-induced recombination on XPA. XP12BE (XPA-deficient) cells were 
transfected with the dual supF  reporter construct containing the pyrimidine motif triplex 
binding site and then transfected or not with the amidate 18 TFO. Parallel samples were 
also transfected with XPA cDNA at the same time as the dual supF  vector. Induced 
recombination was assayed as in Fig. 3 and Fig. 4. (D) Levels of XPA expression in 
XP12BE cells versus XP12BE cells transfected with a XPA cDNA construct. XP12BE 
cells and XP12BE cells transfected with XPA cDNA were collected at 48 and 72 hours 
post-transfection and expression o f XPA was detected by Western blot.
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Figure 7. Serum  stability of pyrim idine TFOs. [y-3 2P]ATP-labeled TFOs were added 
to FBS and aliquots were removed at time points from 0 to 24 hours. The percent 
oligonucleotide remaining represents the amount o f full-length TFO still intact at the 
given time point.
238
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Chapter Three: 
Triplex-Stimulated Intermolecular 
Recombination at a Single-Copy Genomic Target
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
C hap ter Three: Triplex-stim ulated interm olecular recom bination at a single-copy 




Design of reporter cell lines containing a single-copy luciferase gene target 3.10
Design of anti-parallel and parallel motif TFO s............................................................ 3.11
The luciferase reporter gene assay is highly reproducible and sensitive....................3.12
Parallel and anti-parallel motif TFOs induce sequence-specific recombination 3.13
TFO induction of recombination is dose-dependent......................................................3.15





Figure 1A and B. Schematics o f single-copy chromosomal target..............................3.33
Figure 1C. Development of standard mixing curves.....................................................3.34
Figure 2. TFO-induced recombination at a single-copy chromosomal target 3.35
Figure 3. Dose dependence of TFO-induced recombination........................................3.36
Figure 4. The effect o f donor DNA orientation on recombination..............................3.37
Figure 5. The effect o f donor length and modification on recombination..................3.38
Figure 6 . A comparison of chemically modified pyrimidine m otif TFOs.................. 3.39
Figure 7. Camptothecin conjugated TFOs.......................................................................3.40
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
J. M. Kalish
Introduction
Gene targeting via homologous recombination (HR) is well established as a 
research tool to generate knock-out or genetically modified mammalian cells and mice 
[1], However, the technology for gene knock-out depends on selection techniques to 
enrich for cells in which HR events have occurred and to eliminate cells in which off- 
target vector integration has taken place [1 , 2 ]; it does not alter the absolute frequency of 
targeted HR. For gene therapy applications, such techniques are less useful because the 
ability to apply clonal selection to human stem cells is limited. Consequently, most gene 
therapy efforts have focused on the introduction o f cDNAs within expression constructs, 
typically using viral vectors, to complement inherited genetic defects by gene addition 
rather than by HR-mediated gene correction. Integration usually occurs in a non-targeted 
manner, often resulting in sub-optimal expression, inactivation, or even loss of the 
construct. Site-specific gene correction by HR would be preferable to ensure appropriate 
expression and function.
Several approaches are under study to enhance the frequency of targeted HR for 
eventual application to gene therapy. One involves the use of single-stranded viral 
vectors, such as the adeno-associated virus (AAV), that may undergo homology-directed 
integration at increased frequencies [3, 4], However, these vectors can still mediate 
significant levels o f non-homologous integration events [3, 4]. Alternatively, studies 
have demonstrated that the production of site-specific chromosomal damage can 
substantially increase the frequency of homologous recombination by exogenous DNAs
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[5]. In mammalian cells, evidence suggests that the search for homology is not 
necessarily the rate-limiting step for gene targeting [5]. Rather, DNA damage, and in 
particular strand breaks, may be the key step to sensitize the target site for HR. Work 
using rare-cutting endonucleases such as l-Scel has shown that site-directed double­
strand breaks (DSBs) can stimulate HR by 1,000-fold or more [6-11], However, \-Scel is 
not applicable to gene therapy because its use requires the prior introduction of its 18-bp 
recognition site into the genome.
To overcome this limitation, one approach has been the development of artificial 
nucleases with engineered binding domains as tools to create strand breaks at specified 
sites. Recent studies have demonstrated that expression of custom-designed zinc finger 
nucleases (ZFNs) in Drosophila embryos or in mammalian cells in culture can be 
effective at promoting site-directed recombination [12-15]. However, the off-target 
effects o f such ZFNs have not been well-studied.
Another method to create site-specific DNA damage is based on the use of 
triplex-forming oligonucleotides (TFOs). Triplex DNA can be formed when 
oligonucleotides bind as third strands in a sequence-specific manner within the major 
groove of the double helix at polypurine/polypyrimidine stretches. In one motif, a 
pyrimidine-rich oligonucleotide binds in a direction parallel (in terms of 5' to 3' direction) 
to the purine strand in the duplex [16-19], In this so-called pyrimidine or parallel-motif 
triplex, T binds to A:T base pairs (bp) and C binds to G:C bp [16], In the alternative 
purine motif, favored at G:C bp-rich target sites, a purine-rich strand binds anti-parallel to
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the purine strand in the Watson-Crick duplex, with A binding to A:T bp and G binding to 
G:C bp [20-24],
Initial studies testing the use of TFOs to induce recombination focused on the 
coupling of the TFOs to DNA-reactive conjugates, such as psoralen, to deliver site- 
specific DNA adducts that might provoke recombination [25], However, subsequent 
work demonstrated that triple helix formation itself, without any associated covalent 
DNA damage, can stimulate recombination via recruitment of the nucleotide excision 
repair (NER) pathway in episomal shuttle vector targets in human cells or in plasmid 
substrates in cell-free extracts [26, 27], Studies also demonstrated that there is no 
requirement for covalent linkage o f the TFO and the donor molecule, and in the case of 
episomal targets in mammalian cells, there can be substantial distances of several 
hundred bp between the TFO binding site (TBS) and the recombination target [28], In 
other work, it was shown that intramolecular recombination between tandem repeat genes 
at a chromosomal locus can also be induced by TFOs, but intermolecular recombination 
was not tested [29, 30],
Here, we report the ability of TFOs to stimulate intermolecular recombination at a 
single-copy chromosomal locus in mammalian cells. CHO-derived cell lines carrying 
single copies of Firefly luciferase (Flue) genes inactivated by stop codon mutations were 
co-transfected with TFOs designed to form either parallel or anti-parallel triplexes at sites 
upstream of the Flue coding region in combination with single-stranded donor DNAs 
(ssDNAs) of lengths between 30 and 69 nucleotides (nt) carrying wild-type Flue
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sequences. The mixture of the TFOs with the donor DNAs was 5- to 9-fold more 
effective at mediating Flue gene correction and restoring luciferase activity than was 
transfection of the donor DNAs alone. Correction frequencies of up to 0.1% were 
obtained in a TFO sequence-, target site-, and dose-dependent manner. The results 
establish the utility of site-directed triplex formation as a tool to boost gene targeting by 
donor DNAs at chromosomal sites.
M aterials and Methods 
Oligon ucleotides
Oligonucleotides were synthesized by The Midland Certified Reagent Company 
Inc. (Midland, Texas) and purified by RP-HPLC. Oligonucleotide sequences are as 
follows: AG30 (5' AGGAAG GGGGGG GTGGTG GGGGAG GGGGAG 3'); 12AG30 
(5' GGAGGA GTGGAG GGGAGT GAGGGG GGGGGG 3'); s51 (5' TGGTAAAGCC 
ACCATGGAAG ACGCCAAAAA CAT AA AG A A A GGCCCGGCGCC 3'); as30 5' 
(CTTTCTTTAT GTTTTTGGCG TCTTCCATGG 3'); as51 (5' GCCGGGCCTT 
TCTTTATGTT TTTGGCGTCT TCCATGGTGG CTTTACCAAGC 3'); as69 (5' 
CCAGCGGATA GAGTGGCGCC GGGCCTTTCT TTATGTTTTT GGCGTCTTCC 
ATGGTGGCTT TACCAAGCT 3'). AG30 and 12AG30 were 3’-end-protected with a 
C7 amine group. Flue donor molecules including as30, as51, s51, and as69 were 5’- and 
3’-end-protected with three phosphorothioate internucleoside linkages at each end.
Donors with three locked nucleic acid (LNA) residues on each end LNA30, LNA51, and
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LNA69 (of the same sequences as as30, as51, and as69, respectively) were synthesized 
by Eurogentec (Seraing, Belgium). Amidate 18 was obtained from Transgenomic as 
described [31]. The TC18 sequence o f am idatel8  was 5'-TTTTCTTTTT TCTTTTCT-3' 
and consisted of phosphoramidate intemucleoside linkages (3' bridging nitrogen) between 
all nucleosides. The TFO, LNA18, modified with LNAs at every other residue was also 
synthesized by Eurogentec and was of the same sequence as amidate 18. N, N- 
dimethylaminopropylphosphoramidate (aDMAP and pDMAP) and 
diethylethylenediamine (aDEED) TFOs of the TCI 8  sequence with these chemistries 
between all nucleosides were kindly synthesized by Francoise Debart and Jean-Jacques 
Vasseur. (R)-l-0-[4-(l-pyrenylethynyl)phenylmethyl]glycerol, twisted intercalating 
nucleic acid (TINA) TFOs TINA849 and TINA855, synthesized by Vyacheslav Filichev, 
had the following substitutions 5'ttttPctttt ttctPtttctP3’ and 5'UUUUPCUUUUP 
UUCUPUUUPCUa3', respectively, where P is a TINA, a is a C-7 amino group, C is 5- 
methyl-2'-deoxycytidine (5meC), and U is 5-(l-propynyl)-2'-deoxyuridine (pdU) (and c 
and t are unmodified nucleobases). Camptothecin (CPT) (topoisomerase I inhibitor) 
conjugated TFOs were synthesized by Paola Arimondo. The CPT TFOs all have the 
sequence 5'CUCUCUCUCU UUUUUU3’ (where U is pdU and C is 5meC), with a four 
carbon linker conjugated to the 3'-end of the TFO and connected to either 10-carboxy 
camptothecin (TUCL4CPT), two phenol rings (TUCL4Ph2), or linker alone 
(TUCL4NH2). Psoralen was conjugated to the 5'-end o f TUCL4CPT (psoTUCL4CPT) 
and TUCL4Ph2 (psoTUCL4Ph2). The topoisomerase II inhibitors have a (CEFCFFOje
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linker conjugated to the same sequence as above (TUC-C18-ICP165) or to a 20-mer 
(5'CUCUCUCUCUUUUUUUCUCU3’, TUC20-C18-ICP165).
Plasmid vectors
Plasmids containing the Flue gene were created by subcloning of Fluc+ from 
Promega’s pGL3-Basic Vector (Madison, Wisconsin) into pcDNA5/FRT (Invitrogen, La 
Jolla, California) as described [28, 31]. Briefly, an insert containing the duplex AG30 
target or the duplex TCI 8  target was introduced upstream of the Flue ATG start site. 
Nonsense mutations were created via site-directed mutagenesis at bp 13 relative to the 
Flue start codon. Lack of luciferase activity in all mutated Flue vectors was confirmed 
using the Promega Luciferase Assay (see below).
Cell lines
CHO-Flp cell lines were obtained from Invitrogen (Carlsbad, California) and 
maintained according to the manufacturers’ instructions. Cells were transfected with a 
1:10 ratio of the appropriate Flue plasmid to pOG44 (Flp recombinase expression vector) 
to generate the following cell lines: CHO-RWT (AG30 purine TFO binding site, wild- 
type Flue), CHO-R13 (AG30 purine TFO binding site, nonsense mutation at bp 13 of 
Flue), CHO-YWT (T C I8  pyrimidine TFO binding site, wild-type Flue), CHO-Y13 
(TCI 8  pyrimidine TFO binding site, nonsense mutation at bp 13 o f Flue), and CHO-YScr 
(A:T bp-rich site that has 9 mismatches relative to the T C I8  site, with the Flue nonsense 
mutation at bp 13). CHO-YScr and CHO-YScr202 have the TBS, 5'CUCUCUCUCU 
UUUUUU3’ and the Flue nonsense mutation at bp 13 and bp 202 from the start site,
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respectively. Plasmid transfections were carried out using GenePORTER2 Transfection 
Reagent (Gene Therapy Systems, San Diego, California). Cells were placed in 
nonselective media for 48 hours and then placed into hygromycin selection (600 ug/mL); 
colonies were allowed to form and single-copy integration at the expected site was 
confirmed via Southern blot [32],
Establishment o f  relative light unit standards and determination o f  assay sensitivity
Using pairs of matched cell lines mixed in fixed ratios o f wild-type to mutant Flue 
cells, a standard curve was established. Cultures of matched single-copy Flue wild-type 
and Flue mutant cells for each target site set were grown to sub-confluence, detached by 
trypsinization, resuspended in medium and counted to establish cell density (cells/mL). 
The pairs were mixed as follows: CHO-R13 with CHO-RWT cells and CHO-Y13 with 
CHO-YWT cells. The suspensions of the mutant cells (either CHO-R13 or CHO-Y13) 
were adjusted to 1x10s cells per mL, and aliquots o f 50,000 mutant cells were seeded into 
individual wells (4 cm2 /well). Wild-type Flue cells (CHO-RWT or CHO-YWT) were 
adjusted to 5xl 0 4 cells per mT, serially diluted, and then added to the wells containing 
the mutant cells. A range of samples was generated to contain varying proportions of 
wild-type cells mixed with the Flue mutant cells ( 6  replicates per data point). All cell 
cultures were allowed to grow for 48 hours and then the mixed cell populations were 
harvested and lysed. The cell lysates were analyzed for luciferase activity using Promega 
Luciferase Assay Reagent (Promega, Madison, Wisconsin) according to manufacturer’s 
instructions. Relative light units (RLUs) were normalized to the quantity o f protein per
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tested sample. These standards were used as a benchmark for the RLU data. A plot of 
RLU/protein versus percentage of wild-type cells was generated for each experiment, and 
this was used to normalize the experimental data and allow the assignment of 
recombination frequencies to the experimental RLU values.
Chromosomal gene targeting protocol and luciferase assay
CHO-R13 or CHO-Y13 cells were transfected with the single-stranded donor 
DNA oligonucleotides (ssDNAs) and with selected TFOs (AG30, am idatel8 , or control 
oligonucleotides) using Geneporter 2 according to manufacture’s instructions. Briefly,
2 4 24 hours prior to transfection, 12-well plates (4 cm per well) were seeded with 5x10
cells/well. Quantities of TFOs and donor DNAs transfected were as indicated for each
experiment; in all cases transfections were done in triplicate. Forty-eight hours following
transfection, cells were harvested for lysate preparation and analysis of Flue gene
correction. Luciferase activity in the lysates was measured as described above. Data are
presented as fold over donor alone for each experiment and as an absolute percent
recombination. The recombination frequency was calculated based on normalization to
the standard curves. For the DEED and DMAP TFOs, cells were electroporated with 2
pM TFO (Bio-Rad gene pulser; settings: 25 pF, 250W, 280 V; in 0.4 cm electrode gap
cuvette) with oligonucleotide on the first day and a fixed amount o f donor was introduced
24 hours later with GenePORTER2. As a positive control am idatel8  was also
electroporated at a concentration of 0.5 pM. Cells were lysed and measured for induced
recombination 48 hours after donor transfection as above.
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Results
Design o f reporter cell lines containing a single-copy luciferase gene target
In order to test TFO-induced gene correction in an assay representative o f a 
potential gene therapy target, we designed a series o f CHO-derived cell lines each with a 
single chromosomal copy of a mutated version of the Flue reporter gene. In each line, 
the Flue locus was engineered to also contain a polypurine/polypyrimidine site amenable 
to triplex formation situated upstream of the coding region and within 71 bp o f the 
mutation to be corrected. These cell lines were also engineered such that the Flue 
constructs were inserted at the same chromosomal position, an outcome that was 
facilitated by use of a parental CHO cell line with a pre-existing Flp recombinase target 
(FRT) integrated at a single chromosomal site.
For one pair of cell lines, an expression cassette containing the luciferase gene 
downstream of the AG30 TFO binding site (at position -53 bp relative to the start ATG of 
the Flue coding region) was sub-cloned into an FRT-containing plasmid vector. A 
matching plasmid with a nonsense mutation at bp 13 relative to the ATG start site (site- 
to-mutation distance of 6 6  bp) was derived by site-directed mutagenesis. These plasmids 
were separately used to transfect the FRT-containing CHO-Flp cells in conjunction with 
transient expression of the Flp recombinase. The desired cell lines were selected and 
screened as described in the methods section for site-specific integration o f the target 
constructs. The resulting cell lines, CHO-RWT and CHO-R13, each were determined to
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contain a single-copy of the luciferase gene at the standardized integration site, with 
either the wild-type Flue or the Flue 13 nonsense mutant, respectively.
Similar steps were performed to generate the CHO-YWT and CHO-Y13 cell lines 
containing either the wild-type Flue or the Flue 13 mutant downstream of an A:T bp-rich, 
pyrimidine-motif TBS for the TFO, am idatel8 . In addition, a third mutant cell line, 
CHO-YScr, otherwise identical to CHO-Y13 but with a scrambled version of the TCI 8  
site, was established to serve as a target site control. This cell line contains an A:T bp- 
rich target which has 9 mismatches relative to the canonical T C I8  target sequence. The 
site-to-mutation distance in both CHO-Y13 and CHO-YScr is 71 bp. The cell line CHO- 
YScr202 has the same TBS as CHO-YScr but the site to mutation distance is 260 bp.
As with the CHO-RWT and CHO-R13 cells, the CHO-Y cell set was confirmed 
to have the F/wc-containing constructs integrated into the CHO cell genome at the pre­
existing FRT site, as determined by Southern blot analysis (not shown), thereby 
facilitating comparisons among the cell lines. Background luciferase enzyme activity 
was found to be negligible in lysates from all three of the cell lines containing the Flue 13 
genes with the bp 13 stop codon mutation and from the one cell line containing the 
Fluc202 mutation.
Design o f anti-parallel and parallel m otif TFOs
AG30, a G-rich 30-mer TFO, has been previously shown to bind as a third strand 
with high affinity in the anti-parallel triplex motif at the G:C bp-rich duplex target present 
in the promoter regions of CHO-RWT and CHO-R13 (Fig. 1 A). The binding
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characteristics of AG30 for this duplex target have been reported [33], 12AG30 is a G- 
rich 30-mer oligonucleotide containing the same base composition as AG30 but having 
12 mismatches in the third-strand binding code. AG30 and 12AG30 consist of natural 
nucleobases and natural phosphodiester backbones except for end-capping with a propyl 
amine at the 3'-end to inhibit nuclease degradation. Am idatel8  is aN3'->P5' 
phosphoramidate modified, T-rich TFO that binds in the parallel triplex motif to the 
polypurine strand of the duplex target present in the promoter region of CHO-YWT and 
CHO-Y13 (Fig. 1A). It consists of natural nucleobases but contains a fully substituted 
phosphoramidate backbone in which the 3' bridging oxygen is replaced with nitrogen.
This modification has been shown to enhance third strand binding in the pyrimidine motif 
under physiologic conditions [31]. The binding characteristics o f ami date 18 for this 
target site have been described previously [31].
The luciferase reporter gene assay is highly reproducible and sensitive
For each experiment, a standard curve was established to correlate luciferase 
activity with the proportion o f Flue wild-type cells among Flue mutant cells in mixed cell 
populations. Cell lines containing the wild-type copy of Flue and either the AG30 or 
TC18 TFO binding site were mixed in defined ratios from 1:10,000 (0.01%) to 1:3 
(33%) with matched cells containing the same TFO binding site but with a mutated 
version of the Flue gene. Samples consisting of all Flue positive (100%) and all Flue 
mutant cells (0%) were also included. At each increment o f wild-type cell percentage, 
cell lysates were tested for luciferase activity, and RLUs/protein values were determined.
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As shown, there was a highly consistent, linear relationship between RLUs/protein and 
percentage of wild-type cells (Fig. 1C). In addition, this linear relationship was found to 
be essentially identical for both pairs o f cell lines; this result is consistent with the fact 
that all cell lines were constructed to contain a single-copy of the same basic luciferase 
expression cassette in the same genomic locus. The linearity of the relationship between 
luciferase activity and the proportion of luciferase wild-type cells in mixed cell 
populations and the consistency between the two sets of cell lines provided the basis for 
us to compare data between experiments and to assign recombination frequencies based 
on luciferase enzyme activity in cell lysates of treated cells. In addition, the assay was 
found to be highly sensitive, being capable of detecting proportional Flue activity (and 
therefore recombination events) in just 1 in 1 0 , 0 0 0  cells.
Parallel and anti-parallel m otif TFOs induce sequence-specific recombination between 
a genomic target and a single-stranded donor DNA
TFO-induced recombination was tested in both the CHO-R13 and CHO-Y13 cell 
lines. The cells were transfected with either the single-stranded donor DNAs alone or 
donor DNAs plus specific, mismatched, or unrelated control oligonucleotides. Two days 
after transfection, correction of the luciferase mutation was determined by assaying 
luciferase activity in lysates of the treated cells. As shown (Fig. 2A), AG30 plus donor 
induced recombination 5.7-fold over donor alone (0.05% recombination) in the CHO- 
R13 cell line containing the matched G:C bp-rich AG30 binding site upstream of the 
luciferase coding region. However, AG30 had no effect above that o f the donor alone in
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cells containing the A:T bp-rich binding sites (CHO-Y13 or CHO-YScr) at the same 
relative position in the luciferase cassette. Specificity was also demonstrated by the lack 
of effect of 12AG30, an oligonucleotide containing a scrambled version of the AG30 
sequence (creating 12 mismatches to the target sequence in CHO-R13 cells), on donor 
DNA recombination in the CHO-R13 cells (Fig. 2A).
Similarly, am idatel8  induced recombination at a frequency 6.1-fold over donor 
alone (0.07% recombination) in the CHO-Y13 cells containing the matched A:T bp-rich 
binding site for the am idatel8  TFO sequence (Fig. 2B) but not in the CHO-YScr cells 
(containing an A:T bp-rich binding site with 9 mismatches versus am idatel8 ). As further 
evidence o f specificity, am idatel8  had no effect on recombination in the CHO-R13 cells 
with the G:C-rich binding site (Fig. 2B). Additionally, we also tested LNA18, an 
oligonucleotide with the same nucleotide sequence as am idatel8  but containing modified 
2 '-0, 4'-C-methylene bridge ribose moieties. This TFO was previously shown to mediate 
triplex formation in vitro but to lack intracellular targeting activity [31]. LNA18 did not 
induce recombination above that of the donor alone in the CHO-Y13 cell line (Fig. 2B). 
These results show that, in two different CHO cell lines, TFOs can induce intermolecular 
recombination at a single-copy genomic locus in a site-specific manner. In addition, the 
induced recombination was mediated by both purine and pyrimidine TFOs designed to 
form anti-parallel and parallel triplexes, respectively. The specificity o f the reaction was 
demonstrated not only by the lack of stimulation by control oligonucleotides but also by 
the inability of the AG30 and am idatel8  TFOs to induce recombination at luciferase gene
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loci with mismatched target sites.
TFO induction o f  recombination is dose-dependent
Using a fixed amount of donor DNA per transfection sample of 0.2 pg/well (~25 
nM), the amount of TFO in the transfection mix was incrementally increased from 0.1 
pg/well to 0.6 pg/well. In both the CHO-R13 and CHO-Y13 Flue mutant cell lines, there 
was a TFO dose-dependent increase in recombination. In the CHO-R13 cells, at the 
lowest AG30 dose (0.1 pg/well), the fold induction was 3.8, while at the highest dose 
(0.6 pg/well), the fold induction over donor alone was 8.5, corresponding to 
recombination frequencies of 0.03% and 0.07%, respectively (Fig 3A). In the CHO-Y13 
cells, at the lowest am idatel8  dose (0 . 1  pg/well). the fold induction of recombination was 
4.7, while at the highest dose (0.6 pg/well), the fold induction was 9.4, correlating to 
0.06% and 0.11% recombination, respectively (Fig. 3B).
To exclude the possibility that the dose-dependent effects observed could be 
attributable simply to differences in the total quantities o f nucleic acids transfected rather 
than the TFO dose, TFO-induced recombination was tested in the setting o f a constant 
amount of total nucleic acid transfected per sample (Figs. 3C and 3D). In this 
experiment, the sum total amounts of donor DNA and TFO in the transfection mix were 
held constant at 0.6 pg/well; the quantities of the TFOs and donor DNAs were then 
varied in inverse proportion to each other (TFO/donor pairs of 0.0/0 . 6  pg, 0.2/0.4 pg,
0.4/0.2 pg, and 0.6/0.0 pg). In the CHO-R13 cells, increased recombination was seen
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with higher amounts of AG30 (Fig. 3C), even in samples with lower amounts of donor 
DNA (except for the sample with no donor DNA); for example, in the samples containing 
0.2 pg TFO/O.4 pg donor, there was a 2.1-fold induction; in contrast, samples containing 
0.4 pg TFO/O.2 pg donor yielded a 4.1-fold induction. Similarly, with the CHO-Y13 
cells, induced recombination was 3.2-fold (over donor alone) when am idatel8  dose was 
0.2 pg/well and 4.4-fold (over donor alone) when am idatel8  dose was 0.4 pg/well (Fig. 
3D). These results further demonstrate the TFO-dependent stimulation of recombination 
at the Flue chromosomal loci in the two cells lines.
Donor DNA orientation and length
Previous studies focusing on recombination mediated by ssDNAs alone (without 
the use of TFOs) have observed different levels o f activity for DNAs homologous to 
either the transcribed or the non-transcribed strand of the target. Flowever, from target to 
target, no consistent preference has emerged [34, 35], We tested whether there was any 
preference for donor DNA orientation in our assay in the context o f TFO-induced 
recombination. The CFIO-R13 cells were transfected with 0.2 pg/well of either sense 
(matching the non-transcribed strand) or antisense (homologous to the transcribed strand) 
single-stranded 51-mer donor DNAs, with or without 0.2 pg/well o f AG30 (Fig. 4A). 
AG30 was found to boost recombination over both the sense and anti-sense donors alone, 
but the results with the anti-sense donor were superior. Similar results were seen with the 
CHO-Y13 cells and the am idatel8  TFO in the comparison of sense and antisense donors 
(Fig. 4B). Hence, both anti-parallel and parallel third-strand binding induce
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recombination at the Flucl3  target to a greater degree when co-transfected with antisense 
versus sense donor DNAs. Antisense donors were used in all the experiments shown in 
Figures 2 and 3.
To further examine donor DNA characteristics, we compared TFO-induced 
recombination in conjunction with antisense donors of varying length: as30 (30-mer), 
as51 (51-mer), and as69 (69-mer). When co-transfected with am idatel8 , as30, as51, and 
as69 mediated recombination at levels 4.8-, 6.1-, and 3.7-fold over antisense donor alone, 
respectively (Fig. 5A). Hence, the short 30-mer donor was found to be active, but length 
greater than 51 nt did not necessarily yield increased activity. Additionally, we examined 
the effect o f end-modification of the antisense donors with locked nucleic acids in place 
of phosphorothioates at the first and last three positions of the ssDNAs. The LNA- 
modified donors were less effective than the phosphorothioate-modified donors (Figures 
5B and 5C).
Chemically modified TFOs
Other chemically modified TFOs in addition to am idatel8  were examined as well. 
These modifications included the modified base: 5-(l-propynyl)-2'-deoxyuridine (pdU), 
the modified sugars: 2 '-0 , 4'-C-methylene bridged or locked nucleic acid (LNA), and 2'- 
0-(2-aminoethyl)-ribose (2'-AE), and the modified backbones: N, N-dimethylamino- 
propylphosphoramidate (aDMAP and (3DMAP), N, N-diethylethylenediamine (aDEED), 
and (R)-l-0-[4-(l-pyrenylethynyl)phenylmethyl]glycerol, twisted intercalating nucleic 
acid (TINA). Chemical modifications and substitutions on the TFOs for the LNA, pdU,
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2'-AE, DEED, and DMAP are shown in Appendix 1. The 2-AE, pdU, and TINA849 
showed minimal activity in CHO-Y13 cells compared to am idatel8  (Fig. 6 A). Several 
TINA oligonucleotides were tested but the best induction of recombination was 2.9-fold 
over donor for TINA849. The PDMAP oligonucleotide showed low levels of induced 
recombination, 3.1-fold over donor alone (Fig. 6 B). The aDMAP oligonucleotide 
showed slightly higher levels of induced recombination, 4.0-fold over donor alone (Fig. 
6 B). The aDEED oligonucleotide showed 5.7-fold induction of recombination over 
donor (Fig. 6 B). Am idatel8  showed a 7.7-fold induction of recombination when 
electroporated in parallel with the DMAP and DEED TFOs (Fig. 6 B). Percentages of 
induction o f recombination for the pDMAP, aDMAP, aDEED, and am idatel8  were
0.037%, 0.049%, 0.068%, and 0.092%, respectively.
The TINA oligonucleotides were also tested for induced recombination in the 
episomal targeting assay in COS-7 cells as outlined in Chapter 2. TINA849 did not show 
much effect but TINA855 showed an induced recombination frequency of 0.2% 
(compared to 0.37% for amidatel8 ). Finally, the TINA oligonucleotides were tested for 
gene repression in cells containing the wild-type chromosomal target (CHO-YWT cells). 
In the Flue cell lines used here, the luciferase gene is driven by a CMV promoter with the 
TFO binding site just upstream of the transcription start site. Thereby assaying for the 
level of luciferase expression in the wild-type lines allows for detection of inhibition of 
transcription due to TFO binding. The TINA oligonucleotides showed no gene 
repression effect.
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In addition to the chemically modified TFOs mentioned above, TFOs conjugated 
to camptothecin (CPT) were assessed for their ability to induce recombination or 
suppress transcription. Using the cell line CHO-YScr, which contains the target for the 
CPT TFOs and a mutation 13 bp from the Flue start codon and the cell line CHO- 
YScr202 (containing a mutation 202 bp from the Flue start codon), the CPT TFOs were 
analyzed. Recombination between an antisense donor and the chromosomal target was 
induced with the addition of the camptothecin oligonucleotide (TUCL4CPT) at both 
distances in a dose responsive manner (Figures 7A and Fig. 7B). At the 0.2 pg/well TFO 
dose, recombination was induced 2.4-fold over donor alone in CHO-YScr cells (Fig. 7A) 
and 1.3-fold in CHO-Scr202 cells (Fig. 7B), corresponding to 0.03 and 0.02% induced 
recombination, respectively. A greater oligonucleotide concentration was required for a 
similar level of recombination to that seen at the 13 bp distance to be seen at the 2 0 2  bp 
distance.
Additionally, these oligonucleotides were tested for repression o f wild-type 
luciferase activity. Repression observed with the camptothecin oligonucleotide 
(TUCL4CPT) was similar to that seen with the TUCT4NH2 and TUCL4NPh2 controls 
(Fig. 1C). Minimal repression was seen with the topoisomerase II inhibitor conjugated 
oligonucleotides (TUC-C18-ICP165 and TUC20-C18-ICP165) or with the psoralen 
conjugated oligonucleotides (psoTUCL4PH2 and psoTUCT4CPT), with or without 
psoralen activation (data not shown).
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Discussion
The work reported here demonstrates the ability of both purine and pyrimidine 
motif TFOs to induce intermolecular recombination by short single-stranded DNAs at 
single-copy genomic loci in mammalian cells, with induced recombination frequencies of 
up to 0.11%. The TFO-induced recombination was shown to be sequence-specific based 
on comparisons of both mismatched oligonucleotides and mismatched chromosomal 
target sites. A TFO dose-dependence was seen in two sets o f experiments, including one 
in which the total amount of transfected nucleic acid was held constant. Comparisons of 
sense and antisense orientation donor DNAs indicated a preference for antisense donors 
regardless of the orientation of the triplex, and a comparison of donor DNA length 
showed that the 5 1-mer was more active than either the 30-mer or the 69-mer,
This work was facilitated by a sensitive Flue gene assay capable of reporting 
recombination events at frequencies over a wide range, from below 0 .0 1 % to 1 0 0 %.
Based on a consistent linear relationship between luciferase activity in cell lysates and the 
percentage of wild-type cells in mixed cell populations (as established using two separate 
sets of matched cell lines), the assay allows for straightforward calculation of 
recombination frequencies from enzyme activity. The use o f the CHO-Flp parental cell 
line for site-specific introduction of the Flue gene cassettes also provided an additional 
ability to compare TFO-induced recombination in different sequence contexts (and with 
both purine and pyrimidine TFOs) but still at the same chromosomal locus in otherwise 
isogenic cells.
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The similar results in the two cell lines with two different types of TFOs provide 
further evidence for the fundamental ability of triple helix formation to create DNA 
helical distortions that can induce recombinagenic repair events in cells. Of note, there 
were no differences between parallel and anti-parallel binding TFOs vis a vis their ability 
to stimulate recombination. This is in contrast to the distinct effects seen when we 
compare donors homologous to the sense versus antisense strands o f the target duplex. 
Flence, it is likely the extent of helical distortion created by the triplex, not its polarity, 
that confers the ability to stimulate recombination.
Compared to the amidate-modified TFO, LNA, 2'AE, and pdU-modified TFOs 
did not induce significant recombination in the genomic target. The pdU result was 
surprising as it induced recombination in the episomal target. The bulky base may be less 
effective in the single-copy chromosomal target compared to the episomal target. Several 
new chemistries not explored in Chapter 2 were also tested in this genomic target. The 
DEED analogue used in Chapter 2 showed poor binding likely due to the chirality o f the 
phosphorus atom of the phosphoramidate intemucleoside linkages [36, 37], The use of a 
non-natural a anomery instead was proposed to offset this problem. Unlike their P 
analogues, and despite the chirality of the phosphorus atom, these molecules hybridize 
tightly to their DNA targets in an anti-parallel fashion at neutral pFl and without MgCU 
[38]. Between the aDEED TFO, the PDMAP TFO, and the aDMAP TFO, the aDEED 
TFO showed the greatest induction of recombination but that effect was still significantly 
less than that of amidatel 8 . This may have been due to decreased binding to this target
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site or due to decreased delivery. Twisted Intercalating Nucleic Acids (TINA) linkages 
as part o f the backbone structure of the TFO [39] were also tested and none of the TINA 
oligonucleotides induced recombination significantly or repressed wild-type expression. 
The cellular effect of the TINA TFOs has not yet been determined. The TINA TFOs may 
influence intracellular binding or influence repair/recombination/damage recognition 
pathways. Binding of the DMAP and DEED TFOs and the TINA TFOs to the duplex 
used in Chapter 2 was not tested.
The CPT TFOs used in this work showed inhibition of an episomal target in FleLa 
cells [40, 41]. CPT TFOs can recruit topoisomerase I in a sequence-specific manner and 
induce stable cleavage complexes in cell nuclei [42]. CPT TFOs can inhibit transcription 
o f an episomal target only when a cleavage site is present near the TFO end [42]. 
Topoisomerase II inhibitor conjugated TFOs form stable triplexes in vitro [43], but no in 
vivo activity o f these complexes has been detected. The CPT-modified TFO induced 
recombination at low levels in cell lines containing the Flue target mutated at two 
different distances from the TBS. No induction of recombination was seen with the other 
CPT TFOs. Repression of wild-type Flue observed with the camptothecin 
oligonucleotide was similar to that seen with the controls.
It was thought that the intercalation of the camptothecin conjugation would create 
a structure that slows turnover or inhibits repair or recombination. Thus, CPT TFOs 
might create a camptothecin conjugate that blocks topoisomerase I which leads to a 
persistent strand break and therefore a higher likelihood of recombination. In fact, we
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found the opposite; there was a substantial reduction of recombination, suggesting that a 
structure was created that the cell could not resolve. Perhaps merging the amidate 
modification with either the TINA or the CPT modifications would augment the 
effectiveness of induction o f recombination in this or other genomic targets.
The ability of triplex formation to induce repair has been shown to depend on the 
nucleotide excision repair (NER) pathway. In a study using human cell-free extracts, 
TFO-induced intermolecular recombination was blocked by depletion o f the NER 
damage recognition factor, xeroderma pigmentosum group A (XPA) protein, and was 
restored by supplementation of the depleted extracts with purified XPA protein [44], 
Similarly, TFO-induced recombination in an episomal target was absent in human mutant 
cells deficient in XPA but was restored by complementation of the mutant cells by 
expression of XPA cDNA [45], Hence, TFOs exert an effect on recombination by 
engaging the cellular repair machinery to generate recombinagenic intermediates. Initial 
studies demonstrated that DNA strand breaks are produced in the repair o f triplex 
structures, but the exact pattern of repair-related incisions has not yet been mapped [5].
In a sense, the action o f TFOs through cellular DNA repair pathways is conceptually 
similar to the action of exogenous small interfering RNAs through the cellular RNA 
processing pathways.
Recent reports of the ability of ZFNs to induce recombination further demonstrate 
the concept that the generation of site-specific DNA damage is recombinagenic. ZFNs 
and TFOs represent related approaches, in that both are major groove binding molecules
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that can create site-specific DNA damage to stimulate recombination. ZFNs do this via 
the cleavage activity of the fused endonuclease domain. TFOs do this by forming triple 
helices, which are recognized by repair factors, leading to repair-associated strand breaks 
and thereby activating the target site for recombination. However, TFOs are chemically 
synthesized and obviate the need for expression constructs. The general toxicity and 
safety profile o f oligonucleotides has been extensively studied, and specific 
oligonucleotides have already been approved for therapeutic use in humans [46], In 
contrast, there are data suggesting that ZFNs can be toxic to cells when highly expressed 
[14], presumably due to off-target nuclease activity that is not completely regulated by 
the zinc finger domain.
Although TFOs were shown here to induce intermolecular recombination at 
chromosomal sites by short single-stranded DNAs, they may also be effective in 
combination with other DNA molecules, including long single- or double-stranded DNAs 
and even viral vector genomes, such as AAV. In the case o f AAV vectors, it has already 
been demonstrated that INceZ-induced DSBs can stimulate increases in AAV-mediated 
recombination rates [47], Hence, TFO technology may prove to be complementary to a 
number of other approaches that are being developed to mediate gene correction in 
mammalian cells.
Although TFOs have been shown to induce site-directed sequence changes at 
chromosomal loci in cells in culture and even in mice following systemic administration, 
improvements are still needed in the efficiency of gene targeting by TFOs. The
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frequencies of up to 0.1% obtained in this work represent up to 9-fold better than what 
can be achieved by transfection of the donor DNA fragments alone under the same 
conditions. However, efforts to improve intracellular binding properties of TFOs and to 
promote intra-nuclear TFO delivery will be needed to achieve the desired gains in 
efficiency. Nonetheless, the work reported here constitutes an important next step and 
establishes the ability o f TFOs to stimulate the site-directed recombination at 
chromosomal loci in mammalian cells.
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The majority o f this work is currently accepted for publication in the journal Molecular
Therapy with M.P. Knauert and J.M. Kalish as co-first authors. The luciferase
chromosomal target was designed by and the CHO-R13 and CHO-RWT cell lines were
made by Melissa Knauert. The AG30 data was collected with the help of Denise Hegan.
All other cell lines were made by and data collection was done by J.M. Kalish.
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A 3 GAGGGGGAGGGGGAGGAGGGGGGGGAAGGA 5 TFO (AG3C)
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Figure 1A and B. Schematics of single-copy chromosomal targets. (A) Schematic of 
the luciferase reporter gene cassettes in the CHO-R13 and CHO-Y13 CHO cell lines used 
in this work. The sequences and positions of the TFO binding sites (TBS) relative to the 
stop codon mutations in the Flue coding regions are shown with the distance from the 
start of the TBS to the mutation-to-be-corrected indicated below each construct. The 
mutant Flue genes both contain a stop codon mutation 13 bp downstream from the start 
of the coding region, as indicated by the inverted triangle (y ) . The TFOs, AG30 and 
amidatel8 , bind to their respective duplex target sites in the orientations shown; duplex 
TBS orientation is as indicated by the 5' and 3' labels. (B) Schematic of TFO-induced 
recombination and gene correction, with TFO binding to the TBS and alignment of 
single-stranded donor DNAs with the homologous target sequences, as indicated.
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Figure 1C. Development of standard mixing curves. Graph of the relationship 
between the percent Flue wild-type cells among Flucl3  mutant cells in mixed cell 
populations and the luciferase activity in the lysates of the mixed populations as 
measured by RLUs per pg protein. Mixed cell populations were established with the 
indicated proportions o f Flue wild-type cells among Flucl3  mutant cells to establish a 
standard curve. CHO-YWT w/ CHO-Y13 indicates the curve determined by mixing Flue 
wild-type cells containing the Flue target with the A-rich (T C I8 ) TFO binding site and 
the corresponding Flue 13 mutant cells. CHO-RWT w/ CHO-R13 refers to the curve 
determined by a similar analysis of mixed populations of Flue wild-type cells containing 
the G-rich (AG30) TFO target site and the corresponding Flucl3  mutant cells. Six 
replicates were performed per data point, and error bars indicate one standard error above 
and below the experimental mean.
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Figure 2. TFO-induced recombination at a single-copy chromosomal target. (A)
Recombination in CHO-R13 cells induced by the matched sequence-specific TFO, 
AG30. Cells with the indicated TFO binding sites (CHO-R13: G-rich purine motif TBS 
matched to AG30; CFIO-Y13: A-rich pyrimidine motif TBS matched to am idatel8 ; 
CFIO-YScr: A-rich pyrimidine motif TBS mismatched relative to am idatel8 ) were 
transfected with either donor alone (no TFO), donor plus AG30 (specific for the G-rich 
target site) or donor plus 12AG30 (scrambled sequence G-rich oligomer mismatched at 
12 bp versus the target in the CHO-R13 cells); cell lines are indicated by their suffix 
(R13, Y13 and YScr for CHO-R13, CHO-Y13, and CHO-YScr cells, respectively). 
Donor alone sample indicates CHO-R13 cells transfected with 0.2 pg/well of as51; all 
other samples received 0.2 pg as51 and 0.2 pg of the TFO or control oligonucleotide, as 
indicated. Gene correction to produce functional luciferase genes was detected by 
analysis of luciferase enzyme activity in the lysates of the treated cells. Results are 
presented as fold induction over donor alone (ssDNA 51-mer, as51) on the right axis and 
calculated percent recombination on the left axis. 12AG indicates 12AG30 as described 
in materials and methods; all other TFOs are indicated by their full designation as 
described in materials and methods. The frequencies o f induced recombination were 
determined based on RLU/protein measurements and reference to the standard curves in 
Fig. 1C. At least six replicates were performed for each sample, and error bars indicate 
one standard error above the experimental mean. (B) Recombination in CF10-Y13 cells 
induced by the specific TFO, amidatel 8 . Conditions and cell lines are as in (A); LNA 
indicates LNA18 as described in materials and methods.
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Figure 3. Dose dependence of TFO-induced recombination. (A) Dose dependence of 
induced recombination by the G-rich TFO, AG30. CHO-R13 cells were treated with 0.2 
pg/well of as51 donor and increasing amounts of AG30, as indicated. Fold induction of 
recombination over donor alone samples is noted on the left axis and recombination 
frequency is presented on the right axis. The frequencies o f induced recombination were 
determined based on RLU/protein measurements and reference to the standard curves in 
Fig. 1C; at least six replicates were performed for each sample, and error bars indicate 
one standard error above the experimental mean. (B) Dose-dependence of induced 
recombination by the T-rich TFO, am idatel8 . CHO-Y13 cells were treated with 0.2 
pg/well of as51 donor and increasing amounts o f amidate 18 (amidate), as indicated. 
Results are presented as in (A). (C) Triplex-induced recombination in CHO-R13 cells as 
a function o f TFO dose in samples transfected with a fixed total amount of nucleic acids 
(sum of TFO and donor DNAs). In each sample, CHO-R13 cells were treated with 0.6 
pg total nucleic acid/well. Concentrations o f as51 and AG30 were adjusted inversely as 
indicated. Results are presented as in (A). (D) Triplex-induced recombination in CHO- 
Y13 cells as a function of amidate 18 (amid) dose in samples transfected with a fixed total 
amount o f nucleic acids (sum of TFO and donor DNAs), as above (A).
336


























Figure 4. The effect of donor DNA orientation on recombination. (A) Luciferase 
gene correction by co-tranfection of either sense or antisense single-stranded donor 
DNAs and the TFO, AG30. CHO-R13 cell lines were treated with 0.2 pg of either sense 
or antisense 51-mer DNAs with (+) or without (-) 0.2 pg of AG30, as indicated. (B) 
Luciferase gene correction by co-tranfection of either sense or antisense single-stranded 
donor DNAs and the TFO, am idatel8 . CHO-Y13 cell lines were treated with 0.2 gg of 
either sense or antisense 51-mer donor DNAs with (+) or without (-) 0.2 gg of am idatel8  
(amid). All results (A and B) are presented as fold increase in recombination over as51 
donor alone. The frequencies of induced recombination were determined based on 
RLU/protein measurements and reference to the standard curves in Fig. 1C; at least six 
replicates were performed for each sample, and error bars indicate one standard error 
above the experimental mean.
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Figure 5. The effect of donor length and modification on recombination. (A)
Influence o f the length of the single-stranded donor DNAs. CHO-Y13 cells were treated 
with 25 nM of antisense, phosphorothioate end-modified donor DNAs with (+) or 
without (-) 0.2 pg of amidatel8 . Single-stranded donor DNAs tested were of length 30 
nt, 51 nt and 69 nt. (B) Length comparison of LNA donors. CHO-Y13 cells were treated 
with 25 nM of antisense, LNA end-modified donor DNAs with (+) or without (-) 0.2 pg 
o f amidatel8 . (C) LNA versus phosphorothioate donors. A fixed amount (25 nM) of 
donor (either as30 or LNA30 as labeled) was added to each well of CHO-Y13 cells.
Doses of amidate 18 as labeled were added. All results (A, B, and C) are presented as 
fold increase in recombination over as51 donor alone. The frequencies of induced 
recombination were determined based on RLU/protein measurements and reference to the 
standard curves in Fig. 1C; at least six replicates were performed for each sample, and 
error bars indicate one standard error above the experimental mean.
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Figure 6. A comparison of chemically modified pyrimidine motif TFOs. (A) A
number of chemically modified TFOs in the pyrimidine motif were compared.
Amidatel8  (amid), 2'-0-(2-aminoethyl)-ribose (2'-AE), 5-(l-propynyl)-2'-deoxyuridine 
(pdU), and (R)-l-0-[4-(l-pyrenylethynl)phenylmethyl]glycerol, Twisted Intercalating 
Nucleic Acid (TINA)-modified TFOs were compared in CF10-Y13 cells. TFOs are as 
described in materials and methods above or in Chapter 2. (B) A comparison of 
phosphoramidate modified-TFOs. N, N-dimethylaminopropyl-phosphoramidate 
(aDMAP and (3DMAP) and N, N- diethylethylenediamine (aDEED) modified TFOs were 
compared with amidate 18 for induction of recombination in CEIO-Y13 cells, using 
electroporation for delivery of the TFO. as51 was used as the donor at 0.2 pg/well and 
TFOs were added at 2 pM, except for amidate 18 which was added at 0.5 pM. TFOs are 
as described in materials and methods above. All results (A and B) are presented as fold 
increase in recombination over as51 donor alone. The frequencies o f induced 
recombination were determined based on RLU/protein measurements and reference to the 
standard curves in Fig. 1C; at least six replicates were performed for each sample, and 
error bars indicate one standard error above the experimental mean.
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Figure 7. Cam ptothecin conjugated TFOs. (A) TUCL4CPT (CPT) induction of 
recombination in CHO-YScr cells. The dose effect of the CPT-conjugated TFO was 
demonstrated for cells with a mutation 13 bp from the ATG start site of Flue. as51 at 0.2 
pg/well was used as the donor. (B) TUCL4CPT induction of recombination in CHO- 
YScr202 cells. A 51-mer antisense ssDNA homologous to the wild-type Flue sequence 
and flanking the 202 bp mutation was used at 0.2 pg/well. The dose effect of the CPT- 
conjugated TFO was demonstrated for cells with a mutation 202 bp from the ATG start 
site o f Flue. C. Repression of Flue by CPT TFOs. The ability o f CPT TFOs to repress 
wild-type Flue was tested in CHO-YWT cells as compared to a phenyl-conjugated TFO, 
TUCL4Ph2 (Ph2) and an unconjugated TFO, TUCL4NH2 (NH2). TFOs were each 
added at 0.2 pg/well. Results (A and B) are presented as fold increase in recombination 
over as51 donor alone. The frequencies o f induced recombination were determined 
based on RLU/protein measurements and reference to the standard curves in Fig. 1C; at 
least six replicates were performed for each sample, and error bars indicate one standard 
error above the experimental mean. Result C is presented as fraction and percent o f wild- 
type Flue activity as compared to untreated wild-type Flue cells.
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Introduction
Mammalian cells rely on the NER pathway to remove bulky DNA helix- 
distorting lesions (such as pyrimidine dimers) [1]. Unrepaired lesions lead to mutations 
or cell death; thereby NER serves (in conjunction with other repair pathways) to maintain 
genomic integrity. Deficiency in NER is responsible for the three rare autosomal 
recessive diseases, xeroderma pigmentosa (XP), Cockayne syndrome (CS), and the 
photosensitive form of trichothiodystropy (TTD) [2], XP patients exhibit extreme 
ultraviolet radiation (UV) sensitivity and increased incidents o f sunlight-induced cancers 
[2]. XP has been classified into 7 complementation groups, XPA through XPG [2], Each 
group lacks or has a protein deficient in part of the NER complex.
NER involves damage recognition and incision, excision o f the damage, repair 
resynthesis, and ligation [3] (Appendix 2). The NER reaction has been reconstituted in 
vitro [4-6] and the role o f most of the factors involved is known, but the order of 
recognition and associated binding is still the subject of debate. Within the NER pathway 
there are two different sub-pathways based on the transcription status of the DNA 
containing the lesion, transcription coupled repair (TC-NER) and global genome repair 
(GGR) [3]. These pathways differ in their recognition but have a common incision 
process. Dual incisions are made 5-6 nucleotides 3' and 22-24 nucleotides 5' to thymine 
dimers in mammalian cell-free extracts with excision products 27-32 nucleotides long [7, 
8 ]. The location of the incisions has been shown to vary with the type of lesion to be 
repaired [5], XPG makes the 3' incision and XPF-ERCC1 makes the 5' incision [9]. In
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repair of a cisplatin lesion, Evans et al. demonstrated that an open complex forms that is 
dependent on the core NER factors (all but XPF-ERCC1) and the incisions occur near the 
junctions of this open bubble with dsDNA [10]. Cross-link repair may require sequential 
excisions and repair on both strands and/or intra-strand recombination [11-13]. The 
location of the dual incisions in repair of a triplex is not known and would be essential in 
uncovering the mechanism of triplex repair.
Previous work in the Glazer lab demonstrated that triplex-induced mutagenesis 
and recombination is dependent on the nucleotide excision repair (NER) pathway [14- 
17]. Triplex-induced repair and recombination requires XPA, a NER recognition factor 
[16, 18, 19]. A 10 nucleotide TFO, conjugated to psoralen, and mono-adducted to duplex 
DNA produces excision products while a 30 nucleotide TFO does not produce excision 
products [20]. The gene modification activity o f the 30-mer TFO, despite the lack of 
excision products suggests that multiple repair pathways may function in triplex repair. 
This idea is also consistent with the fact that the length of attachment of some TFOs (i.e. 
TFOs 30 nucleotides long) exceeds the canonical excision span of NER.
The mechanism of triplex repair is not currently understood and these 
experiments are designed to illuminate aspects of this mechanism. To understand the 
mechanism of triplex action and to elucidate the pathway by which triplexes promote 
repair and recombination, the incision step o f the bulky adduct created by triplex binding 
needs to be mapped. The nature o f these excision products and the location o f the 
incisions have not been previously evaluated, and those are the goals of this work. In
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order to ultimately develop an assay to locate the sites o f incision made in repair o f a 
TFO bound to duplex DNA, strides were taken to create substrates with altered helical 
structures to address this question.
In order to determine the biochemical nature of the excision of a triplex structure 
from DNA, a number of factors need to be considered. First, the repair pathways 
involved include at least NER, but given that NER alone cannot excise a 30-mer TFO 
bound to duplex DNA, other repair pathways are likely to be active as well. Second, in 
order to understand the biochemical mechanism of the incisions, the excision products 
themselves need to be visualized and deciphered. Finally, the complexity o f these 
incisions and the alteration of incisions based on different altered helical structures by 
different TFOs need to be addressed. In the work presented in previous chapters, repair 
of pyrimidine motif triplexes was shown to be dependent on NER (as has been previously 
demonstrated for purine motif triplexes). Additionally, binding affinity alone is not 
sufficient for induction o f repair and recombination. Chemical modifications that are 
more helically distorting are more inducing of repair and thereby more inducing of 
recombination. In attempting to capture excision products, a variety o f techniques have 
been attempted as outlined here, and while some have been more productive than others, 
they demonstrate that there is at least one incision occurring in repair o f 15-mer and 24- 
mer TFOs.
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pso-AG30, pso-5'AGGAAGGGGG GGGTGGTGGG GGAGGGGGAG3’; pso- 
NewlO, 5'pso-AGGAAGGGGG3'; pso-Newl4, 5'pso-AGGAAGGGGG AGGG3'; pso- 
New23, 5'pso-AGGAAGGGGG AGGGAGGGGA GGG3'; and pso-New29, 5’pso- 
AGGAAGGGGG AGGGAGGGGA GGGAGGGGG31 were synthesized by Oligos, Etc.
32psoNewl 1, psoNewl5, psoNew24, and psoNew30 were created by adding [a- P]ddA 
(Amersham Biosciences) to the 3'-end of psoNewlO, psoNewl4, psoNew23, and 
psoNew29 as described below. IC1, 5'GGGACCTGAA CACGTACGAA 
ATTCGATATC CTCTAGCCAG ATCTGCGCCA GC3'; IC2, 5 'T G AGGGGG AG 
GGGGTGGTGG GGGGGGAAGG ATC3'; IC3, 5'TTGGGCTGCA GCAGGTAGAC 
TCTAGAGGAT CACGAGCGAA CTCTAATGCA CC3'; IC4, 5'CAGATCTGGC 
TAGAGGATAT CGAATTTCGT ACGTGTTCAG GTC3'; IC5, 5’TGCAGCCCAA 
GATCCTTCCC CCCCCACCAC CCCCTCCCCC TCAGCTGGCG3'; IC6 ,
5'TTGGTGCATT AGAGTTCGCT CGTGATCCTC TAGAGTCTAC CTGC31; Newl 1,
5'AGGAAGGGGG A3'; Newl3, 5'AGGAAGGGGG AGG3’; Newl5,
5'AGGAAGGGGG AGGGA3'; New20, 5'AGGAAGGGGG AGGGAGGGGA3';
New24, 5'AGGAAGGGGG AGGGAGGGGA GGGA3'; New30, 5'AGGAAGGGGG 
AGGGAGGGGA GGGAG GGGGA3'; NEWPUR, 5'GGTACCGAAT TTCGGCCAGG 
GGGAGGGAGG GGAGGGAGGG GGAAGGATTC GAACCTT3'; and NEWPYR, 
5 'AAGGTTCGAA TCCTTCCCCC TCCCTCCCCT CCCTCCCCCT GGCCGAAATT
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CGGTACC3' were synthesized by W.M. Keck Foundation Biotechnology Resource 
Laboratory (Yale University). Newl 1, N ewl5, New24, and New30 are of the same 
sequence as psoNewl 1, psoNewl5, psoNew24, and psoNew30, described above without 
the psoralen on the 5'-end and the [a- P] ddA on the 3'-end.
CHO cell-free extracts
CHO cells were harvested from forty 15 cm dishes and centrifuged at 3000 rpm 
for 10 minutes at 4°C. Cells were washed twice with 10 times packed cell volume (PCV) 
of cold PBS, resuspended in 4 PCVs o f 10 mM Tris-HCl pH 7.5, 1 mM EDTA, and 5 
mM DTT, and incubated on ice for 20 minutes. Resuspended cells were homogenized 
and 4 PCVs of cold 50 mM Tris-HCl pH 7.5, 10 mM MgCh, 2 mM DTT, 25% sucrose, 
and 50% glycerol were added. 1 PCV of saturated ammonium sulfate (4.2 M, pH 7.2) 
was added drop wise and stirred for 30 minutes, following the last drop, at 4°C. The 
sample was then centrifuged at 45000 rpm in Ti70 rotor for 3 hours at 4°C. The 
supernatant was collected and the volume was measured, and 0.33 g o f ammonium 
sulfate per mL of supernatant was added slowly. Then 100 pL 1 M NaOH/10 g 
ammonium sulfate was added and stirred for 30 minutes at 4°C. The sample was then 
centrifuged at 12000 rpm in a SS34 rotor for 30 minutes at 4°C. The pellet was 
resuspended in dialysis buffer (25 mM HEPES-KOH, pH 7.9, 100 mM KC1, 12 mM 
MgCb, 0.5 mM EDTA, 2 mM DTT, 15% glycerol) using 1/20 pellet volume of the 
supernatant and dialyzed at 4°C for 3 hours followed by another 3 hours with fresh 
dialysis buffer. The dialysate was centrifuged at 14000 rpm in Eppendorf tubes in a
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microcentrifuge for 20 minutes at 4°C. This protocol was kindly given to us by 
Tadayoshi Bessho. Aliquots of 100 pL were made and frozen in liquid nitrogen. Protein 
concentrations were measured by Bradford assay [21].
Linear substrates
pNEWAG and pNEWTC were constructed from pIND/lacZ (Invitrogen) by 
cloning into the BamHI restriction site following the annealing o f ssDNAs, 
5'GCAGAAAGCG GATCCTTCCC CCTCCCTCCC CTCCCTCCCC CTAGAGACTT 
GTTCG3' and 5'CGAACAAGCT TCTAGGGGGA GGGAGGGGAG GGAGGGGGAA 
GGATCCGAAG CTTTCTGC3' that were synthesized by W.M. Keck Foundation 
Biotechnology Resource Laboratory (Yale University). The distinction between 
pNEWAG and pNEWTC is the orientation of the TBS. A 195 bp fragment was cut out 
of these plasmids with Kpnl and XmnI, gel purified, and when not used in conjunction 
with end-labeled TFOs these substrates were 5'-end-labeled with [y- P]ATP (Amersham 
Biosciences). Following phenol-chloroform extraction, TFOs were bound to this 
substrate and following mono-adduct formation, subjected to the incision reaction, as 
described below. Alternatively, one of two 57mers was end-labeled and annealed with its 
unlabeled complement.
End-labeled TFOs
TFOs (pso-NewlO, pso-Newl4, psoNew23, and pso-New29) were designed with 
psoralen on the 5 '-end so that [a- P]ddA could be added to the 3 '-end to complete the 
oligonucleotides (pso-Newl 1, pso-Newl5, pso-New24, and pso-New30). [a-3 2P]ddA
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was added via terminal transferase (New England Biolabs) per manufacturer instructions. 
The synthesized sequences were as shown above and the final sequences were pso- 
Newl 1, 5'pso-AGGAAGGGGG A3'; pso-Nwl5, 5'pso-AGGAAGGGGG AGGGA3'; and 
pso-New24, 5'pso-AGGAAGGGGG AGGGAGGGGA GGGA3'; pso-New30, 5’pso- 
AGGAAGGGGG AGGGAGGGGA GGGAGGGGGA3'. In vitro binding and mono- 
adduct formation were done as described below. Samples were concentrated in 
microconlOOs (Millipore), incision was as described below, then 10 pL of 2.5x 
formamide dye was added, samples were boiled for 5 minutes and loaded onto 15% 
polyacrylamide gels.
Internally labeled substrates
A double stranded 137 bp fragment was also built from 6  ssDNAs (IC1-IC6 as 
described above). One of the six ssDNAs was 5'-end-labeled with T4 kinase and 
[y-3 2 P]ATP prior to construction and the remaining 5 ssDNAs were kinased together.
The ssDNAs were mixed, phenol-chloroform extracted, ethanol precipitated, and 
resuspended in DNA dilution buffer (Roche, Rapid ligation kit). The sample was heated 
to 65°C for 10 minutes and then cooled at 23°C, for 20 minutes, then ligation buffer and 
ligase were added. Samples were incubated at 23°C for 2 hours and then for 18 hours at 
4°C. Gel purification was as described below followed by in vitro binding as below. 
Plasmid substrates
psupFGl, a plasmid containing the AG30 TBS sites was used as a plasmid 
substrate. In vitro binding was done as described below with psupFGl and pso-AG30
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followed by mono-adduct formation as described below. After the incision reaction 
described below, samples were resuspended in water and restriction enzyme cuts 2 0 0  bp 
apart were made and the fragments were separated on a 12% polyacrylamide gel. DNA
32was transferred to a membrane and probed with oligonucleotides labeled with [a- P]CTP 
(Amersham Biosciences). The probes were designed to contain all or part o f the AG30 
TBS. An internally labeled plasmid was created by cutting pMM2 [22] with BamHI (a
T9cut at the end of the TBS), end-labeled with [y- P] ATP, religated, and then used as the 
plasmid substrate for TFO binding and incision. In vitro binding, mono-adduct 
formation, and the incision reaction were as below. Following the incision reaction, stop 
reaction, phenol/chloroform extraction, and ethanol precipitation, a restriction digest was 
done as above.
In vitro binding
For linear substrates, 5 jug substrate and 10 //M TFO were used. For plasmids, in 
vitro binding was with 3 jug plasmid and 10 //M TFO. In all cases, binding was 
performed in 10 mM Tris (pH 7.6), 10 mM MgCB, 1 mM spermine, and 50% glycerol at 
37°C for 16 hours.
Third-strand binding assays
Third-strand binding was measured using gel mobility shift assays under native 
conditions. Two complementary 30-mers (NEWPUR, NEWPYR) containing the NEW 
TBS target were synthesized. Duplex DNA was prepared by mixing 1000 pmol o f each 
57-mer together with 50 mM NaCl, incubating at 85°C for 20 minutes, and cooling to
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room temperature before end-labeling with T4 polynucleotide kinase (New England 
BioLabs) and [y-3 2 P]ATP. Duplex was gel purified, electroeluted, and filtered by
o
centricon3 (Millipore). A fixed concentration o f duplex at 5 x 10" M was added to 
binding reactions with increasing concentrations of oligonucleotides in 2 0  pi containing 
10 mM Tris (pH 7.6), 10 mM MgCE, and 1 mM spermine. Samples were incubated at 
37°C for 16 hours and were loaded onto 15% polyacrylamide gels 
[acrylamide/bisacrylamide (19:1)] containing 17.8 mM Tris and 17.8 mM boric acid (pH 
7.6) and 10 mM MgCh and the gels were run in the same concentration of Tris-boric acid 
and M gCf at 60 V for 6  hours at 23 °C.
Mono-adduct formation
To establish optimum mono-adduct formation and minimum cross-link formation, 
a range of times from 10 seconds to 6  minutes at 320 nm were evaluated. TFOs were 
bound to the 57-mer duplex, UVA treated for the indicated time, and visualized on a 15% 
polyacrylamide denaturing gel. Ten seconds at 320 nm was used for most o f this work. 
Removal o f unbound and unadducted TFO
To dissociate unadducted TFO following mono-adduct formation, 10 mM Tris 
(pH 8 ), 1 mM EDTA, and 100 mM KC1 were added to the binding reaction and incubated 
for 2 hours at 60°C. Samples were cooled to 23 °C and concentrated in microconlOOs, 
rinsed with water, and then incision reactions were performed as below.
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Gel purification of substrates with mono-adducted TFOs
Prior to incision, TFO mono-adducted substrate was resolved on 10% denaturing 
gels and the DNA of the correct size was electroeluted from the gel in lx  TBE for two 
hours at 15 mA, spun in a centricon30 (Millipore), concentrated in a microcon3 
(Millipore), washed with water, and subjected to the incision reaction.
Incision assay
The incision reaction consisted of, lOx repair buffer (0.3 M HEPES-KOH (pH 
7.9), 0.4 mM KC1, 32 mM MgCl2, 2 mM DTT, 1 mM EDTA (pH 8 )), 100 mM ATP, 10 
mg/mL BSA, 250 ng DNA substrate, and 100 jug o f CHO cell-free extracts. Incision 
reactions were incubated for 1 hour at 32°C. Reactions were stopped by adding 1 pL of 
10% SDS and 1 pL o f 20mg/mL proteinase K (Sigma) and incubating at 37°C for 15 
minutes, followed by phenol-chloroform extraction and ethanol precipitation. Glycogen 
(Sigma) was added to aid in precipitation of small DNA fragments. Samples were 
resuspended in 2.5x formamide dye solution, analyzed on a 12% polyacrylamide gel run 
at 65W for 2 hours. If samples were not previously labeled, DNA was transferred to 
membranes as described above. Otherwise gels were dried and analyzed on a 
phosphorimager (Storm 860, Molecular Dynamics, Amersham Pharmacia Biotech). This 
protocol was given to us by Tadayoshi Bessho.
Size standards
To monitor unbound TFO and for smaller size standards Newl 1, Newl3, N ewl5, 
New20, New24, New30 were 5'-end-labeled via T4 kinase with [y-3 2P]ATP.
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The initial substrate to be used is a 195 bp duplex (either NEWAG or NEWTC) 
with a 3'-end-labeled TFO with a 5'-psoralen bound and mono-adducted just 5' o f the 
TFO binding site (TBS) on the purine strand of the duplex (Fig. 1 A). Also explored in 
this work are 195 bp duplexes (NEWAG and NEWTC) that are 5'-end-labeled followed 
by TFO binding and mono-adduct formation (Fig. IB). Lastly, internally labeled 
duplexes are formed through ligation o f 6  ssDNAs, one o f which is 5'-end-labeled prior 
to ligation (Fig. 1C). IC2 is labeled in Fig. ICi, IC3 in Fig. ICii, and IC6  in Fig.ICiii. 
Incision activity o f  CHO cell-free extracts
In order to ensure excision activity of the cell-free extracts and our ability to 
detect the excision products, a 6-4 photo-adduct containing an internal radiolabel (a kind 
gift from Tadayoshi Bessho) was used. Excision of this 6-4 photoproduct was performed 
with extracts we made and the canonical excision pattern was seen (Fig. 2). The excision 
products ranging from 24 to 27 nucleotides in length with the primary product being 27 
nucleotides were seen only in the presence of active cell-free extracts and were absent in 
the mock reaction without extracts. The amount of excision products was as expected for 
this substrate.
In vitro binding o f  3'-end-labeled TFOs
The initial substrate for incision was a linear 195 bp fragment in conjunction with 
a series of 3'-end-labeled TFOs in the purine motif. To 3'-end-label the TFO,
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T9dideoxyadenine was the only available P labeled dideoxynucleotide, therefore the 
purine TFO sequence had to be redesigned to have an adenine in the appropriate places to 
allow for comparison of different length TFOs 3'-end-labeled with [a-3 2 P]ddA. Binding 
studies were done with these TFOs at pFI 7.6 with 10 mM MgCE and 1 mM spermine to 
a 57-mer duplex substrate made o f NEWPUR/NEWPYR. The dissociation constant (Kj), 
the molar concentration of TFO where half of the duplex substrate is bound to the TFO, 
was determined for each TFO. Newl 1 did not have a detectable K<j. Newl5, New20, 
New24, and New30 had Ka’s of 10"9, 10'8, 10'8, 10' 9 M, respectively (Fig. 3). To create 
the appropriate TFO target for these TFOs, their TBS site was cloned into pIND/lacZ in 
both orientations. The linear substrates, NEWAG and NEWTC were cut out of this 
plasmid with XmnI and Kpnl creating a 195 bp linear fragment. NEWAG had the purine 
strand of the TBS 5' to 3' and NEWTC had the pyrimidine strand 5' to 3' in the plasmid. 
Mono-adduct formation fo r  incision substrates
Psoralen TFOs were chosen because cross-linking or mono-adducting psoralen to 
the plasmid substrate provided a greater likelihood of the TFO being present during the 
incision reaction in cell-free extracts. Given our interest in the TFO being adducted to 
the strand to which the TFO is bound and not to both strands of the duplex, the efficiency 
of mono-adduct formation with a given substrate needed to be determined. While 
previous work in the Glazer lab showed 12 minutes at 447 nm was optimum for mono- 
adduct formation and 6  minutes at 320 nm was optimum for cross-link formation [23], 
with these substrates and the psoNew TFOs 10 seconds at 320 nm proved optimum for
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mono-adduct formation (Fig. 4). These results are for the pso-NewlO TFO and are 
representative of the other pso-New TFOs used in this work. Lanes 1, 3, 5, 7, and 9 
contain labeled duplex alone without TFO. Lanes 2, 4, 6 , 8 , and 10 contain labeled 
duplex bound to TFO prior to exposure to UVA. The lanes without TFO did not show 
any mono-adduct or cross-link formation. Given that this is a denaturing gel, only mono- 
adducted or cross-linked structures, which are both larger than the duplex, will move 
more slowly through the gel matrix. A TFO mono-adducted to one duplex strand is 
larger than the strand alone and a TFO cross-linked to both strands of the duplex is even 
larger. The smallest bands (seen in all lanes) represent the duplex while the slightly 
larger bands (seen in Lanes 2, 4, 6 , 8 , and 10) indicate mono-adduct formation between 
one of the duplex strands and the TFO. The largest bands (seen in lanes 2, 4, 6 , 8 , and 
10) indicate cross-link formation between the TFO and both strands o f the duplex. With 
time of UVA exposure increasing, mono-adduct formation decreases and cross-link 
formation increases. The optimum mono-adduct formation and minimal cross-link 
formation occurs at 10 seconds of UVA exposure.
Incision with 3'-end-labeled TFOs on linear substrates
Using psoNew24 with NEWAG and NEWTC linear substrates (unlabeled) 
binding, mono-adduction, and incision are as above. In Fig. 5, Lanes 1 and 2 show 
psoNew24 TFO only. The banding represents the psoNew24 TFO alone with its dimer 
and possible G-quartet (as this is a G-rich TFO). Lane 3 shows NEWAG with psoNew24 
bound, mono-adducted, and incubated with CHO cell-free extracts. This lane shows a
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small amount of large intact substrate, a middle size product (G-quartet formation), a 
smaller prominent product (unbound TFO), and a smaller ladder o f possible incision 
products. Lane 4 shows NEWAG with psoNew24 bound, mono-adducted, and incubated 
with all of the same conditions as Lane 3 except dialysis buffer alone was added in place 
of cell-free extracts. This lane shows more intact substrate, G-quartet formation, 
unbound TFO, and less possible incision products. Lanes 5-9 show end-labeled Newl 1, 
New 15, New20, New24, and New30, respectively. Recall that since the TFO carried the 
label, only fragments adducted to the TFO or TFO complexes alone are seen. The 
resulting image indicated a major product between 19 and 23 nucleotides in length (Fig.
5, Lane 3). This approximate size was determined by comparison to psoNew24 alone 
(Lanes 1 and 2) and end-labeled Newl 1, New 15, New20, New24, and New30 in Lanes 
5-9.
The signal distinction between the amount o f this product with and without 
extract was small (compare Fig. 5, Lanes 3 and 4) and confounded by the fact that the 
labeled TFO ran at about the same size. Therefore, removal of the unbound TFO was 
necessary to confirm that these products were indeed excision fragments and not unbound 
TFO. To this end following TFO binding and mono-adduct formation, TFO binding was 
disrupted and size filtration was used to remove excess, unbound, and unadducted TFO 
[22] (Fig. 6 A). Labeled TFO allows for monitoring of the removal o f unbound TFO with 
size separation columns. Size filtration removed most o f the unbound psoNew24 TFO, 
but a ladder similar to that seen in Fig. 5, Lane 3 remained (Fig. 6 B). Gel purification on
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a 1 0 % denaturing gel was also employed and the yield of large substrate alone (and no 
small ladder) is shown in Fig. 6 C.
The products resulting from incision after size purification showed a different 
pattern from the pre-purification results (Fig. 7). Lanes 1 and 2 showed the flow-through 
from each size filtration wash. Lane 3 shows NEWTC and psoNew24 bound, mono- 
adducted, and incubated with CLIO cell-free extracts. Lane 4 shows the same binding 
and adduction, but mock incubation. Lane 5 shows NEWAG and psoNew24 incubated 
with cell-free extracts. Lane 6  shows the same substrate with a mock incision reaction. 
Lane 7 shows psoNew24 alone. Lanes 8-11 show end-labeled Newl 5, New 20, New24, 
and New30. Note that the lanes with substrate and TFO but without extract (Lanes 4 and 
6 ) look similar to the flow through lanes (Lanes 1 and 2) for all small products.
However, comparing the large bands in Lane 3 to Lane 4, and Lane 5 to Lane 6 , there is a 
product slightly smaller than the initial substrate in both lanes containing extracts (see 
arrows). After only size filtration, there were some small fragments o f excision size with 
extract present but without extracts the amount o f labeled TFO was still overwhelming 
possible fragments (Fig. 7). The presence of small excision fragments was still 
confounded by remaining psoNew24 TFO. However, it appears that there are larger 
products (closer in size to the initial substrates) that are present only when cell-free 
extracts are present and absent in the mock incision reaction. Given that the expected 
products were small, this gel (Fig. 7) was not run far enough to significantly separate the 
larger products.
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In order to clarify the nature of these products and to determine if the small 
fragments were excision products or unbound TFO, gel purification on a 10% denaturing 
gel was done with the TFO bound and mono-adducted substrate prior to the incision 
reaction. The purified substrate was electroeluted out of the gel and then the triplex 
structure was allowed to re-form prior to the incision reaction. In Fig. 8 , Lane 1 shows 
NEWAG and psoNewl5, bound, mono-adducted, and incubated with cell-free extracts. 
Lane 2 shows the same substrate and TFO, bound, and mono-adducted but mock 
incubated. Lane 3 shows NEWAG and psoNew24, bound, mono-adducted, and 
incubated with cell-free extracts. Lane 4 shows the same substrate and TFO, bound, and 
mono-adducted but mock incubated. Note in both Lanes 1 and 3 there are two products 
smaller than the 195 bp substrate and TFO (see arrows), these products are not present in 
Lanes 2 and 4 (with the mock incision). Lanes 5 and 6  show the substrates and TFO 
without the mock or actual incision reaction. Lanes 7-10 show end-labeled New30, 
New24, New20, and N ewl5, respectively. The purified substrate used for incision in 
Fig. 8  is visualized in Fig. 6 C.
Following this extra purification step, there was a trace amount of small product, 
but there was minimal difference of this product between the incision reaction and the 
mock reaction (Fig. 8 , compare Lane 1 to 2 and Lane 3 to 4). The major difference 
between the incision reaction products and the mock reaction was seen in the production 
of two fragments smaller than the initial substrate but too small to be the excision 
fragments that would be expected if a dual incision reaction occurred and the TFO-
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adducted fragment was released. These products suggest that a single incision was made 
on one side or the other of the TFO mono-adducted and bound to the duplex. Since the 
TFO was labeled, only the strand adducted to the TFO was detected and the products 
visualized in Fig. 8  contain the TFO and some part of the initial substrate.
Internally labeled substrates
In order to locate the site o f this incision, an internally labeled substrate was 
designed. This internally labeled substrate was similar to that used in previous work 
studying incision o f thymine dimers [7, 8 ], This internally labeled substrate was built by 
ligating 6  ssDNAs together, one o f which was 5'-end-labeled prior to ligation. The 
internally labeled duplex was designed to be 137 bp long. The construction of the duplex 
is shown in Fig. 1C. Any one or more of the ssDNAs can be 5'-end-labeled before 
ligation, yielding several possible locations of a radioactive label on the substrate. The 
construction o f these duplexes requires a gel purification step to completely isolate 
ligated products and to remove partially ligated products (Fig. 9). Lane 1 shows the 195 
bp NEWAG substrate for size comparison. Lane 2 shows radiolabeled IC2 and minimal 
partially or fully labeled product. Lane 3 shows radiolabeled IC3 with fully and partially 
ligated products and IC3 alone. Lane 4 shows radiolabeled IC 6  with fully and partially 
labeled ligation products and IC6  alone. Lanes 5 and 6  show IC3 and IC6  alone, 
respectively. IC2 was smaller and not visualized on this gel. The IC fragments to 
construct this 137 bp duplex ranged in size from 33 nt to 52 nt and several partially 
ligated products can be seen in Fig. 9. Fragments of 85 bp and 94 bp represent partial
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ligations while fragments of 44 bp and 52 bp represent unligated IC 6  and IC3, 
respectively. Very little full size 137 bp substrate is present.
In attempts to increase the yield of the internally labeled substrate, ratios o f the 
ssDNAs and the amount of labeled ssDNA were varied. Ligation time and the ssDNA 
that was labeled were also varied and ssDNAs were gel purified prior to ligation. The 
amount of labeled ssDNA was scaled up markedly to 10 pg in order to increase the 
amount of 137 bp product. This substrate was limited in both yield, as the final ligation 
product showed a very low yield, and time, as the radioactive signal was time sensitive. 
No data was collected with this substrate to date.
Incision with linear end-labeled substrates
All substrates were end-labeled with radioactivity and the binding of the TFO to 
the substrate and mono-adduct formation was verified visually on a denaturing gel. 
Therefore the TFO bound state of the substrate could be verified and the percent of bound 
versus unbound substrate calculated and unbound TFO could be removed if  necessary. 
Linear substrate duplexes allowed detection of the fragment between the incision and the 
5'-end of the duplex. The 5'-end-labeled duplex substrate was easy to create in large 
quantities by restriction enzyme digestion of the appropriate plasmid containing the TBS. 
With these duplex substrates it was difficult to follow the fragment with the TFO 
adducted to it (the potential excision fragment).
4.19
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
J. M. Kalish
Incision with plasmid substrates
The plasmid substrate psupFGl which contains a TBS for AG30 was used with 
pso-AG30 as the TFO. The plasmid substrate required an additional step o f restriction 
digestion to cut out a fragment small enough to be visualized on a polyacrylamide gel 
(about 200 bp). Additionally, since the plasmid was not internally labeled, the products 
were run on a gel, transferred to a membrane, and then probe hybridization was attempted 
to analyze the products. Probes to the AG30 target site and surrounding sequence were 
used. Although size filtration was used to remove unbound TFO from the sample mix 
before the incision reaction was carried out, probes could also bind to the remaining 
unbound TFO, and differentiating between excess TFO and incision products was 
difficult. Results with this substrate and method were limited and difficult to interpret. 
Attempts to use an internally labeled plasmid and a 3'-labeled TFO with a plasmid did not 
show positive results, perhaps due to loss of products in the extra restriction enzyme step 
required prior to visualization on a gel.
Discussion
Determining the nature o f the incision products required forming a specific triplex 
structure, incubating that structure with the cell-free extracts for the incision reaction to 
occur, and then visualizing the products. Each of these steps had several obstacles to be 
overcome in order to create and visualize triplex products. Based on previous work in the 
Glazer lab, incisions were thought to be made 3' and 5' of the TFO when bound to the
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TBS in removal o f a 10-mer TFO [14], potentially analogous to the incision pattern seen 
in excision of a thymine dimer [7, 8 ]. However, a 30-mer TFO (AG30) did not yield a 
similar excision product. This led us to speculate that while NER may still make 
incisions near the triplex lesion, the “wing-span” of the NER complex cannot straddle 
such a large lesion/helical distortion. However, to test whether or not single or double 
incisions do occur, several approaches were considered.
The most promising approach used was a 3'-end-labeled TFO on a linear 
substrate, as the fragment bound to TFO could be tracked. The incision products detected 
have to be attached to the TFO because only the TFO was labeled. The confounding 
signal caused by the unbound TFO could be removed by size filtration and gel 
purification. The large size of the products was surprising given that the TFOs used were 
a 15-mer and a 24-mer and not a 30-mer. This suggests a different mechanism of 
excision compared to repair of a 10-mer. This mechanism may be similar to that for the 
30-mer or could represent an entirely different mechanism. Previous notions of incision 
of a 10-mer but not a 30-mer were based on repair of intermediates of a TFO adducted to 
a plasmid [25], While we have shown that these products are smaller than the initial 
substrate and represent a fragment adducted to the TFO, the exact location o f the incision 
and the nature o f these products remains to be determined.
Labeling the TFO at the 3'-end (as there is psoralen on the 5'-end) allows for the 
fragment with the mono-adduction to the TFO to be tracked following incision. This 
fragment should be o f a different mobility than the labeled TFO alone, and may have a
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Y-like structure (if the mono-adduct is still intact). This approach also allows for the 
direct comparison of different TFO lengths of the same sequence. One drawback o f this 
approach is that the nature of the excision products will require deciphering a y-shaped 
structure and will require synthesis of a complex ladder o f y-shaped structures of varying 
lengths to determine the length of the excision fragment and the location of the incision.
Additional approaches such as the internally labeled substrate can be used to 
decipher these products. The internally labeled substrate offers the advantage of mobility 
of the label. And perhaps further increases in the scale of the ligation can increase the 
amount of the fully ligated product. End-labeling the NEWAG and the NEWTC 
substrates instead of labeling the TFOs will allow for determination of the other products 
present in the incision reaction. The end-label approach uses a 195 bp fragment that is 
easy to make but the potential, labeled, incision product is a larger fragment representing 
the distance from the end of the initial substrate to one incision. Thereby the excised 
fragment if there is one, will not be visualized directly. Running samples in parallel with 
the TFO labeled in one sample, the substrate labeled in a second sample, and both labeled 
in a third sample will help piece together all o f the fragments present after incision.
A complementary approach which has not yet been explored is to monitor 
transcription around these incisions to perhaps detect the location at which the incision is 
made based on where the polymerase falls off the substrate. This method has been used 
to detect peptide nucleic acids bound to a plasmid substrate [24], The concept being that 
a disruption in the template could block transcription, whereas in this case either a
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disruption caused by the altered helical structure or incisions made in repair of this 
structure could disrupt transcription and the location of this disruption can be mapped.
Using a plasmid substrate had the advantage of not introducing radioactivity until 
the last step but the disadvantage o f using small fragment probes which bound to 
unbound TFO as well. Given that the incisions were likely to be in close proximity to the 
TBS, based on data showing that mutation frequencies are highest in the TBS and 
specifically near the psoralen mono-adduct or cross-link site [26], probing for the incision 
products requires including some of the TBS in the probe and therefore most probes 
binding to the incision products would also bind to free TFO remaining in the sample. 
There was no means to visually check this substrate because only the probe was 
radioactively labeled, thereby only the fragments adhering to the probe would be 
visualized. This approach is appealing because a variety o f probes can be used to map 
the resultant excision products. Flowever, these probes are likely to pick up unbound 
TFO as well.
Future directions of this work require extensive purification of the 137 bp 
substrate with internal labels. Additionally, end-labeling the 195 bp NEWAG and 
NEWTC fragments in order to attempt to detect the same larger products seen in Fig. 5 
when the substrate is labeled instead of the TFO is a priority. Additionally, a similar 
repetition with the 137 bp internally labeled fragment would help to further isolate the 
location of the incision.
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Once the incision sites for the psoralen mono-adducted TFO pso-New24 is 
confirmed by using these other substrates, the other 3'-end-labeled pso-New TFOs should 
be used in conjugation with these substrates. A comparison of the incision patterns 
between the different TFOs will suggest the TFO length limitation for the fragment 
excision as compared to the single incision. Additionally, TFOs in the pyrimidine motif 
can be evaluated and unconjugated TFOs in both motifs can be compared. Finally, 
peptide nucleic acid (PNA)-modified TFOs can be evaluated and compared. In summary, 
these techniques allow the location o f incisions in repair of triplexes to be unveiled and 
thereby an important step towards understanding the mechanism o f triplex activity is 
made.
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Figure 1. Substrates for incision assay. (A) 3'-end-labeled TFO with psoralen mono- 
adducted to the purine strand of the TBS on the 195 bp duplex. (B) 195 bp duplex 
(NEWAG and NEWTC) 5'-end-labeled with a psoNew TFO bound and mono-adducted. 
(C) Internally labeled substrates, i. IC2 fragment was 5'-end-labeled prior to ligation, ii. 
IC3 fragment was 5'-end-labeled prior to ligation, iii. IC6  fragment was 5'-end-labeled 
prior to ligation.
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Figure 2. Verification of CHO cell-free extracts activity and visualization method.
Lanes 1 and 2 contain a 6-4 photo-adduct in an internally labeled substrate. CHO cell- 
free extracts were added to Lane 1 and a mock incision reaction was added to Lane 2. 
Lane 3 contains an end-labeled New30 and Lane 4 contains end-labeled Newl3 as size 
markers.
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Figure 3. In  vitro binding affinity of New TFOs. TFOs of different lengths were 
bound to a 57 bp end-labeled duplex and binding affinity was determined by the 
dissociation constant (Kd) which is the concentration of TFO where half of the duplex is 
bound to TFO and half is unbound, under the given set o f conditions (10 mM Tris, pH 
7.6, 10 mM MgCh, 1 mM spermine). The bands of reduced mobility relative to the 
duplex alone represent triplex formation.
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Figure 4. Mono-adduct versus cross-link formation with New TFOs. Using the same 
57 bp duplex used in Fig. 3, the time of UVA exposure required to maximize mono- 
adduct formation was determined using psoNewlO. Lanes 1, 3, 5, 7, and 9 represent 
duplex alone without psoNewlO. Lanes 2, 4, 6 , 8 , and 10 represent duplex with 
psoNewlO bound as described in Fig. 3. Lanes 1 and 2 were treated with UVA at 320 nm 
for 10 seconds. Lanes 3 and 4 were treated for 30 seconds. Lanes 5 and 6  were treated 
for 1 minute. Lanes 7 and 8  were treated for 3 minutes. Lanes 9 and 10 were treated for 
6  minutes.
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Figure 5. Incision of linear substrate adducted to a 3'-end-labeled TFO. Lanes 1 and 
2 show 10 pM and 100 uM of psoNew24 alone. Lane 3 shows NEWAG and psoNew24, 
bound, mono-adducted, and incubated with CHO cell-free extracts. The arrow indicates 
excision products. Lane 4 shows the same binding, mono-adduction, and incubation in 
the same buffers as Lane 3, but no cell-free extracts were added. Lanes 5, 6 , 7, 8 , and 9 
show end-labeled Newl 1, N ewl5, New20, New24, and New30, respectively.
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Figure 6. Purification of incision substrate. (A) A substrate containing the triplex 
binding of NEWAG (a 195 bp linear substrate) and psoNew24 followed by mono-adduct 
formation. (B) The substrate after disruption o f triplex binding and size filtration to 
remove excess, unbound TFO. (C) Gel purification of the substrate.
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Figure 7. Incision of a substrate after size filtration. Lanes 1 and 2 show the flow­
through as purification by size filtration proceeded. Lanes 3 and 4 show psoNew24 
mono-adducted to NEWTC. CHO cell-free extracts were added to Lane 3 and a mock 
reaction was added to Lane 4. Lanes 5 and 6  show psoNew24 mono-adducted to 
NEWAG. CHO cell-free extracts were added to Lane 5 and a mock reaction was added 
to Lane 6 . Lane 7 shows psoNew24 alone. Arrows indicate possible incision products 
and asterisks indicate substrate (NEWAG or NEWTC with psoNew24). Lanes 8-11 
show end-labeled New30, New24, New20, and N ew l5, respectively.
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Figure 8. Incision of a purified, linear substrate adducted to psoralen TFOs. Lane 1 
shows NEWAG and psoNewl5, bound, mono-adducted, and incubated with cell-free 
extracts. Lane 2 had the same substrate but was mock incubated without extracts. Lane 3 
shows NEWAG and psoNew24, bound, mono-adducted, and incubated with cell-free 
extracts. Lane 4 had the same substrate but was mock incubated without extracts. Lanes 
5 and 6  show substrates NEWAG with psoNewl5 and NEWAG with psoNew24 without 
extract incubation or mock incubation, respectively. Arrows indicate possible incision 
products and asterisks indicate substrate (NEWAG with psoNewl5 or with psoNew24). 
Lanes 7-10 showed end-labeled N ewl5, New20, New24, and New30, respectively.
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Figure 9. Construction of an internally labeled duplex. Lane 1 shows a 195 bp 
double stranded fragment. Lane 2 shows a ligation with IC2 labeled, fragment sizes 
within this lane include 137 bp, 85 bp, and 33 bp. Lane 3 shows a ligation with IC3 
labeled, fragment sizes including 137 bp, 85 bp, and 52 bp are seen. Lane 4 shows a 
ligation with IC6  labeled, fragment sizes o f 137 bp, 94 bp, and 44 bp are seen. Lane 5 
shows the 52 bp fragment (IC3) and Lane 6  shows the 44 bp fragment (IC6 ) alone. 137 
bp is the size of the fully ligated product (see arrow).
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Gene targeting via homologous recombination (HR) offers a potential strategy for 
therapeutic correction of mutations in disease-related human genes. However, there is a 
need to improve the efficiency of site-specific recombination by transfected DNAs. 
Oligonucleotide-mediated triple helix formation has been shown to constitute a DNA 
lesion sufficient to provoke DNA repair and thereby stimulate recombination. Triplex- 
forming oligonucleotides (TFOs) bind to duplex DNA in a sequence-specific manner and 
are potential tools to achieve targeted gene modification. Initial studies demonstrated the 
ability of TFOs to deliver mutagenic agents in a DNA site-specific manner. Gene 
modification with TFOs includes induced recombination between a DNA target and a 
donor DNA molecule, a process that allows a TFO to exert an effect at a distance from 
the third-strand binding site. It was also found that TFOs in the purine motif can induce 
gene modification in chromosomal DNA via the effect of the triple helix itself but thus 
far, the effect of the pyrimidine motif TFO alone has not been demonstrated.
The work presented here expands the number of possible target sites for TFO- 
induced gene correction by demonstrating the effect of pyrimidine TFOs, independent of 
a DNA reactive conjugate, to induce recombination and repair. However, the ability of 
triplex-forming oligonucleotides to induce recombination between a target locus and a 
donor DNA was so far previously demonstrated only with multi-copy episomal targets in 
mammalian cells. This work demonstrates the activity of purine and pyrimidine motif 
TFOs in a single-copy chromosomal target. Previous work in the Glazer lab 
demonstrated that triplex-induced mutagenesis and recombination is dependent on the
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nucleotide excision repair (NER) pathway [1-4]. The mechanism o f incision o f a triplex 
during repair is not currently understood and these experiments are designed to illuminate 
aspects o f this mechanism.
We established that a number of chemically modified TFOs in the pyrimidine 
motif showed enhanced binding affinity. These included N3'->P5' phosphoramidate 
(amidate), 5-(l-propynyl)-2'-deoxyuridine (pdU), 2 -0 , 4'-C-methylene bridged or 
locked nucleic acid (LNA), 2'-0-methyl-ribose (2'-0-Me), and 2'-0-(2-aminoethyl)- 
ribose (2'-AE)-modified TFOs. Other chemical modifications such as N, N- 
diethylethylenediamine (DEED), 5-methyl-2'-deoxycytidines (5meC), and morpholino 
(morph) which we expected to show enhanced binding affinity based on previous use of 
these modifications for antisense and other gene modification technology did not show 
such affinity.
Enhanced binding affinity was necessary but not sufficient to induce 
recombination in cells and repair in cell-free extracts as only the amidate and pdU- 
modified TFOs showed such activity. The amidate TFO showed similar induction of 
recombination to that demonstrated previously with the purine m otif TFO, AG30, in an 
analogous reporter system. The amidate-induced recombination, like the AG30-induced 
recombination, was shown to be dependent on XPA. The amidate effect was not based 
on enhanced nuclease stability compared to the other chemically modified TFOs tested. 
These results show that amidate and pdU-modified TFOs can be used as reagents to 
stimulate site-specific gene targeting without the need for conjugation to DNA-reactive
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molecules. The biological activity o f the more DNA-like TFOs (amidate and pdU) 
demonstrated here and the lack of activity of the more RNA-like TFOs (LNA, 2'-0-Me, 
2'-AE) in conjunction with NMR data by Asensio et ah, which showed that triplexes with 
a DNA third strand are more helically distorting than those with a RNA third strand [5], 
suggests that greater helical distortion favors greater recognition by DNA repair 
mechanisms and therefore greater induction of recombination.
The efforts to test a series of chemical modifications on the third strand presented 
here led to the identification of the amidate modification as an inducer of recombination 
and repair based on the effect of the TFO alone. Demonstrating for the first time that an 
unconjugated TFO in the pyrimidine motif is biologically active and thereby, increasing 
the number of target sites possible for gene correction. These efforts provide a 
standardized screening method for testing novel chemical modifications as they are 
developed. Since the initial publication of the amidate work, we screened several new 
modifications but found that the amidate was still the most effective modification tested.
The biological activity of the amidate demonstrated above was in an episomal 
target in cells or in cell-free extracts. In order to demonstrate gene correction with TFOs 
as a model for gene therapy, a single-copy chromosomal target was designed using the 
firefly luciferase reporter gene. CHO cell lines containing triplex binding sites upstream 
of & firefly luciferase gene containing a stop codon, were made with purine and 
pyrimidine binding sites, respectively. The cell lines all had the same integration site for 
the TBS and reporter gene and cell lines with the wild-type luciferase gene were also
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made. The sensitivity o f the assay was determined to be less than 0.01%, where one 
wild-type cell could be detected among 10,000 mutant cells. Gene correction was 
achieved when TFOs were contransfected with single-stranded DNA donors at 
frequencies up to 0.1%. The TFO-induced correction was target site, sequence, and dose 
dependent.
The pyrimidine TFO, amidatel8, and the purine TFO, AG30, showed similar 
levels o f gene correction, demonstrating that correction was independent of the 
orientation of the TFO. Antisense DNA donors (homologous to the transcribed strand of 
the duplex) were more effective in inducing recombination in conjuction with TFO 
binding than sense donors. The 51-mer donor, end-modified with phosphorothioate 
linkages was most effective compared to a 30-mer and 69-mer donor and to LNA- 
modified donors. In comparison to other chemically modified TFOs in the pyrimidine 
motif, the amidate modified-TFO showed the highest percentage o f induced 
recombination. In total, this work demonstrated the effectiveness of TFOs in targeting a 
single-copy chromosomal target and suggests the usefulness of TFOs as sequence- 
specific gene modification tools.
Finally, we developed an assay to detect incisions made in repair of a triplex. We 
demonstrated the excision activity of cell-free extracts and designed a triplex substrate to 
detect incisions. This substrate consisted of a 195 bp duplex and a TFO with a 5'- 
psoralen and a 3'-radiolabel. The TFO was bound to the duplex, mono-adducted, size 
filtered, and gel purified. The purified substrate was incubated with cell-free extracts or
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mock-incubated without extracts. Using a 15-mer and a 24-mer TFO, incision products 
were detected in repair o f a triplex. These products were smaller than the initial substrate 
and similar for both the 15-mer and the 24-mer TFO bound substrates. Smaller excision 
fragments were not detected. This work represents first steps towards understanding the 
nature of incisions made in repair of a triplex structure. Future work will further 
investigate the nature o f the incisions detected here. Placing the radiolabel at different 
locations along the duplex DNA will allow for a more precise location of where the 
incisions were made.
Future directions of TFO technological development include the identification of 
novel chemical modifications to further enhance the biological activity o f TFOs and the 
development o f new techniques for TFO delivery to enhance the biological effectiveness 
of these reagents. Additionally, further steps towards identifying the mechanism of repair 
of a triplex such as the exact nature o f the incisions and the nature o f involvement of 
repair pathways besides NER need to be made. The interplay between the different 
repair pathways at work in repair of a triplex lesion is not understood and future 
directions of this work lie in deciphering these interactions.
In summary, our work suggests that high-affmity DNA binding ligands, such as 
TFOs, can be used to mediate site-specific genome modification. This capacity derives 
not only from the ability of TFOs to bind as third strands with sequence specificity but 
also from the ability of the resulting triple helices to provoke repair, leading to directed
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